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1. Microvascular invasion in hepatocellular carcinoma is not only influenced 
by tumor characteristics but also by changes in the adjacent 
non-cancerous tissue. (This thesis) 
2. The increased expression of placental growth factor and vascular 
endothelial growth factor receptor-1 in the tissue adjacent to hepatocellular 
carcinoma can stimulate the generation of abnormal vessels that are 
permissive to invasion. (This thesis) 
3. The microvessels evaluated in microvessel density scoring do not 
represent the microvessels involved in microvascular invasion. (This thesis) 
4. The association of microvascular invasion in hepatocellular carcinoma with 
the disappearance of Epithelial-Cell-Adhesion-Molecule positive ductules 
signifies the involvement of epithelial-mesenchymal transition (This thesis). 
5. Combination therapy of interferon-a with sorafenib may improve the 
outcome of sorafenib monotherapy in a selected group of patients with 
hepatocellular carcinoma. (This thesis) 
6. Microvessel density in hepatocellular carcinoma is not an appropriate 
parameter to evaluate the efficacy of anti-angiogenic drugs. (This thesis) 
7. Pegylated interferon has a stronger antitumor effect than non-pegylated 
interferon. (This thesis) 
8. I no naka no kawazu, taikai wo shirazu. (A frog in a well does not know the 
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Primary liver cancer, of which hepatocellular carcinoma (HCC) represents the major 
subtype accounting for 85% to 90%, is the sixth most common cancer globally, and 
the third most common cause of cancer-related death [Ferlay et al, 201 0]. HCC 
usually occurs in cirrhotic livers following longstanding chronic inflammation of the 
liver regardless of its etiology. Hepatitis B virus (HBV) or Hepatitis C virus (HCV) 
infection, alcohol related liver disease, obesity and some metabolic disorders such 
as diabetes are major risk factors for chronic liver disease, subsequent cirrhosis and 
potential development of HCC. There are huge geographic variations in the 
incidence rates of HCC. The areas of high incidence are eastern and south-eastern 
Asia and Africa because Hepatitis B and/or Hepatitis C are endemic in these areas 
[EI-Serag, 2011]. In Western countries the incidence rate of HCC is lower, yet 
increasing because of other risk factors, such as obesity and type II diabetes 
mellitus. 
Cancer treatment strategy is usually based on the Tumor Nodes Metastases 
staging system which incorporates the size and extent of the primary tumor, the 
status of regional lymph nodes, and the existence of distant metastasis. For HCC, 
liver disease stage, such as the Child-Pugh classification is also important to 
determine the treatment strategy and to predict prognosis. Current staging systems 
for HCC include both tumor and liver disease stage. The Cancer of the Liver Italian 
Group (CLIP) scoring system incorporates tumor morphology, the existence of 
portal vein thrombosis, the value of a-fetoprotein (AFP), and Child-Pugh stage [The 
CLIP investigators, 1998] and has been well validated world wide as a staging 
system predictive of prognosis. The Japan Integrated Staging (JIS) score combines 
Child-Pugh score and TNM stage based on the Liver Cancer Study Group of Japan 
[Kudo et al., 2003], and a new system incorporating the JIS score and the value of 
serum tumor markers: AFP, AFP-L3, Des-y-carboxy prothrombin (DCP), has 
recently been proposed [Kitai et al., 2008]. These two proposed scoring systems 
from Japan were better prognostic systems than the CLIP score among the 
Japanese patient groups [Kudo et al. , 2004; Kitai et al., 2008], yet further external 
validation is required [Marrero et al., 201 O]. The Barcelona Clinic Liver Cancer 
(BCLC) staging system is much more intended to determine a therapeutic option for 
individual patients with HCC, rather than to predict prognosis [Llovet et al., 1999]. 
The widely applied BCLC treatment strategy includes tumor stage, performance 
status and liver function, and links the stage of the disease to a specific treatment 
option. Briefly, very early or early stage of the disease is linked to the curative 
treatment options consisting of surgical resection, liver transplantation or local 
ablation. The intermediate stage to transarterial chemoembolization (TACE) and the 
advanced stage to sorafenib therapy which are both palliative treatments while the 
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terminal stage can only be addressed by symptomatic treatment [Bruix and 
Sherman, 2011 ]. 
An important factor that contributes to the limitations of therapeutic 
management of HCC is the fact that by far the majority of HCC develops in patients 
with cirrhosis. Liver cirrhosis represents longstanding chronic liver disease with 
serious clinical complications, such as portal hypertension and progressive loss of 
specific liver functions. Hence, the therapeutic intervention of HCC requires a 
combined approach of aggressively dealing with a malignant tumor and careful 
consideration of a diseased organ with limited capacity of regeneration in a sick 
patient. 
Liver transplantation (LT) is regarded as a curative treatment for HCC which is 
associated with the lowest risk of tumor recurrence. Selection of HCC patients for 
LT is usually based on the Milan criteria [Mazzaferro et al., 1996] which states that 
patients with solitary HCC of 5cm or less in diameter, or 2 or 3 HCC nodules of 
which each tumor is 3cm or less in diameter, are considered eligible for LT. The 
patients within these criteria have an expected 5-year overall survival rate of 70% 
with recurrence less than 10% after LT, which is similar to the 5-year survival rate of 
non-HCC individuals [Colombo et al., 2013]. Since organs available for LT are so 
scarce and the number of patients requiring LT far exceeds the number of organs 
available, these criteria can not be rigidly applied. Surveys on extending the criteria 
seem to allow limited adjustment. The Metroticket investigator study group carried 
out the analysis of patients with HCC beyond the Milan criteria who underwent LT, 
which was a retrospective, and so far the largest study [Mazzaferro et al., 2009]. 
Through their study, they set up a prognostic model based on the size of the largest 
tumor, number of tumors and microvascular invasion (micro-VI), all of which are 
regarded as independent prognostic factors, and found that patients with micro-VI 
negative HCC beyond the Milan criteria but within the so called "Up-to-Seven" 
criteria, where the seven refers to the sum of the size (cm) of the largest tumor and 
number of tumors, have a similar acceptable 5-year survival to those with micro-VI 
positive HCC within the Milan criteria. This finding suggests that this particular 
patient group beyond the Milan criteria might be eligible for LT. However, there is no 
tool predictive of micro-VI before transplantation, and therefore, it is not 
recommended that indication of LT should rely on micro-VI [Clavien et al., 2012]. 
Besides the dilemma of micro-VI, their study also highlighted the difficulties of 
radiological assessment of size and number of tumors, as documented repeatedly 
[Sotiropoulos et al., 2005 & Taouli and Krinsky, 2006]. Substantial numbers of 
patients classified as being beyond the Milan criteria preoperatively (444 patients, 
28.5%) fell within these criteria after pathological evaluation, and had an excellent 
survival similar to those within the Milan criteria [Mazzaferro et al., 2009]. 
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Both surgical resection and radiofrequency ablation (RFA) are potentially 
curative, and show excellent short-term outcome among patients with early or very 
early stage HCC. The former is eligible for non-cirrhotic patients and the latter for 
cirrhotic patients or those who have liver dysfunction. According to a recent report, 
no significant difference in 5-year suNival rate is obseNed between these two 
therapies after adjusting covariates among patients with very early or early stage 
HCC [Wang et al, 2012]. There is another report that showed significant difference 
in overall survival between these two therapies [Karabulut et al., 2012]. In addition, 
since these therapies have no effect on underlying chronic liver disease, the 5-year 
disease free suNival is as low as 50.8% in the resection group and 14.1 % in the 
ablation group with surgical resection being superior to RFA [Wang et al., 2012]. 
For a long period, there was no standard treatment for patients with 
unresectable HCC. TACE showed a suNival benefit among patients who have 
multiple HCCs without extrahepatic metastasis or vascular invasion and preseNed 
liver function, and became a standard treatment for patients with intermediate stage 
HCC [Llovet and Bruix, 2003; Raoul et al., 2011]. It has recently been shown that 
TACE using drug eluting beads can improve patients' suNival [Burrel et al., 2012]. 
TACE is used for patients with earlier stage HCC as well, who are not eligible for 
local ablation therapy due to tumor location [Colombo et al, 2013], and can also be 
used for patients on the waiting list for LT as a bridging therapy [Clavien et al., 2012]. 
An oral multikinase inhibitor, sorafenib, is the first molecular targeted drug which 
has been approved for advanced HCC in 2007 by the US Food and Drug 
Administration. The Sorafenib Hepatocellular Carcinoma Assessment Randomized 
Protocol (SHARP) trial revealed efficacy of sorafenib in the treatment of HCC, i.e., 
both median suNival and time to progression showed 3-month improvements by 
sorafenib therapy [Llovet et al., 2008]. Following the clinical success of sorafenib in 
the treatment for advanced HCC, research efforts are now performed on 
combination therapy of other drugs or surgical treatments with sorafenib. 
In summary, HCC has become a global threat due to an increasing global 
incidence with relatively limited therapeutic options since curative treatment is only 
adequate for early stages and only a few therapeutic choices are available for 
non-surgically treatable patients. Furthermore there are no reliable markers to 
assess prognostic factors such as micro-VI before treatment. 
Aims of the thesis 
This thesis addresses two issues related to the prognosis of HCC, micro-VI and the 
sensitivity of HCC to interferon-a (IFN-a). The first part consists of studies on the 
pathogenetic background of micro-VI and in the second part the effects of IFN-a 
therapy are evaluated on the proliferative capacity of the tumor. Although micro-VI 
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is recognized as a vital prognostic factor, its pathogenesis is not well understood. In 
chapter 2 the available methods to predict micro-VI before surgery are reviewed. 
The studies in chapter 3 and 4 are designed to gain insight in the pathways that are 
involved in micro-VI and to establish a possible profile of tumors containing or 
lacking micro-VI. The studies are tissue based and were executed on archival tumor 
tissue of patients who underwent LT (chapters 3 & 4). HCC is a heterogenous 
cancer due to its various etiologies, hence its sensitivity to several types of 
anti-cancer drugs is variable. Based on the sorafenib outcomes we studied whether 
additional effects of combination therapy with IFN-a/sorafenib could be observed. In 
chapters 5 & 6 we studied the effects of IFN-a administration with and without 
combination with sorafenib on several HCC-cell lines. The effects of both types of 
therapy were investigated by measuring the proliferative capacity of the tumor cells 
followed by subsequent in vivo experiments in nude mice. 
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Part I. Microvascular Invasion in HCC 
The significance of microvascular invasion 
Vascular invasion is defined as the presence of tumor cells within the vascular 
space in peritumoral tissue, and in HCC it commonly involves the local branches of 
portal and/or hepatic veins. In general, vascular invasion can be classified as 
macrovascular invasion (macro-VI) and micro-VI. Macro-VI is grossly recognizable 
and therefore detectable by conventional imaging modalities such as computed 
tomography (CT), magnetic resonance imaging (MRI), and ultrasonography. It is 
well known that macro-VI is a predictor for poor prognosis in patients with HCC 
[Llovet et al. , 1999]. Due to a poor prognosis the preoperative diagnosis of macro-VI 
as determined by the above-mentioned imaging techniques is a contraindication to 
treat HCC with LT, surgical resection, local ablation therapy, or TACE [Bruix et al. , 
2011; EASL-EORTC, 2012]. According to the BCLC staging, HCC with macro-VI is 
classified into the advanced stage of the disease linking to the recommendation of 
sorafenib therapy, provided that the patient's performance status and liver function 
are preserved [Bruix et al. , 2011; EASL-EORTC, 2012]. Among patients with the 
sorafenib treatment median overall survival is about 11 months [Llovet et al, 2008]. 
Similarly, micro-VI has also been shown to negatively influence the prognosis 
of HCC either after LT or resection. Rodriguez-Peralvarez et al reported in their 
review paper by using meta-analysis that the presence of micro-VI shortens the 
disease free- and overall survival after LT and disease free survival after surgical 
resection [Rodriguez-Peralvarez et al. , 2013]. Overall survival and recurrence rate 
after surgical resection was clearly stratified when the extent of vascular invasion 
was categorized into no vascular invasion; micro-VI or macro-VI [Roayaie et al. ,  
2009]. Another notable finding about the influence of micro-VI, among patients who 
underwent LT for HCC, 3- and 5-year survival rates were almost the same between 
patients with micro-VI positive HCC within the Milan criteria and patients with 
micro-VI negative HCC beyond the Milan criteria but within the "Up-to-seven 
criteria" [Mazzaferro et al. , 2009]. The 5-year survival rate was more than 70% in 
both groups which is regarded as acceptable performance after LT for HCC. This 
suggests that patients with micro-VI negative HCC beyond the Milan criteria but 
within the "Up-to-seven criteria" could have been candidates for LT if micro-VI was 
detectable preoperatively, who are now excluded from a waiting list for LT due to 
being beyond the Milan criteria. 
A major drawback of micro-VI is that in contrast to macro-VI, identification of 
micro-VI can only be done by histopathologic examination. Hence, by definition its 
diagnosis depends on the availability of tumor tissue. In practice, micro-VI can only 
be reliably diagnosed after surgical resection of the tumor. On a biopsy, evaluation 
of micro-VI may easily lead to sampling error. Another serious disadvantage of 
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micro-VI is the absence of widely recognized markers to predict the presence of 
micro-VI before surgery. This is a major obstacle to predict the tumor behavior and 
subsequent tailoring of the therapy of choice for HCC patients. 
In chapter 2 the available methods of predicting micro-VI before surgery is 
reviewed [Gouw et al., 2011]. Firstly, we investigated the relationship between 
micro-VI and tumor characteristics. Many studies showed a significant correlation 
between micro-VI and size and number of tumor. However it is to be noted that the 
size and number of tumor were evaluated pathologically after surgery, not 
radiologically before surgery. Since it is not easy to evaluate the size and numbers 
of tumor accurately in a cirrhotic liver, there is always some degree of discrepancy 
between radiological and pathological evaluation and this discrepancy is an 
absolute limitation of patient selection. Although several papers from Japan showed 
a significant correlation between micro-VI and gross classification proposed by the 
Liver Cancer Study Group of Japan, the same limitation exists. On the other hand, 
the advantage of radiological examination compared with the pathological one is 
that it ·is possible to evaluate the hemodynamics of the tumor. Witjes et al reported 
that the presence of washout demonstrated on dynamic contrast enhanced MRI 
was significantly associated with histological grade and micro-VI which are closely 
correlated with each other [Witjes et al., 2012]. Kim et al showed that peritumoral 
hypointensity seen on the hepatobiliary phase of gadoxetate disodium-enhanced 
MRI (Gd-EOB-MRI) is predictive of micro-VI [Kim et al. , 2012]. Gadoxetate 
disodium is a recently-introduced hepatocyte specific contrast agent which allows to 
evaluate hemodynamics and hepatocyte's function of focal liver lesion at once. So 
far, Gd-EOB-MRI has become an indispensable tool in clinical practice for HCC. 
Further study regarding identification of micro-VI on Gd-EOB-MRI is needed. 
Serum biochemical markers were also studied as a possible predictor of 
micro-VI before surgery. In some studies, a significant correlation was shown 
between micro-VI and the increase or rapid progression of AFP which is a 
conventional tumor marker for HCC [Pawlik et al. , 2005; Vibert et al., 2010]. 
However AFP can be high with other liver diseases, so it is used in conjunction with 
AFP-L3 which is more HCC-specific. DCP, also known as protein induced by 
vitamin K absence or antagonist II (PIVKA-11), is another representative tumor 
marker for HCC, and has been shown to be associated with micro-VI [Kaibori et al., 
201 O]. There is no correlation between the serum levels of AFP and DCP in patients 
with HCC, suggesting that each tumor marker is reflecting a different tumor 
characteristic. It is considered that AFP is associated with tumor differentiation and 
DCP with metabolic dysfunction of tumor hepatocytes, but the mechanism of 
elevation of these markers are not fully understood. Murata et al showed that the 
increased expression of DCP was induced by hypoxia on HCC cells [Murata et al., 
201 O]. Moreover it was recently shown that the elevation of DCP is seen in patients 
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with HCC after sorafenib therapy [Ueshima et al., 2011]. These two recent findings 
suggest that the elevation of DCP may predict the presence of micro-VI, possibly 
due to hypoxia induced by microthrombus of portal vein. Further study is needed to 
clarify the mechanisms of elevation of these markers. 
Other than AFP and DCP, paraoxonase 1 (PON1) has recently been 
introduced by Huang et al as a promising serum marker for micro-VI in HCC, which 
was identified by proteomic analysis [Huang et al. , 2013]. Minguez et al has shown 
that a 35-gene signature of vascular invasion identified by genome-wide 
gene-expression profiling improve the diagnostic accuracy for micro-VI of tumor 
size. [Mfnguez et al., 2011]. More recently, Pote et al have found N-term acetylated 
histone H4 dimethylated at lysine (K)20, and acetylated at K16 were strongly 
expressed in HCC with micro-VI, which was identified using imaging mass 
spectrometry analysis [Pote et al., 2013]. Thus, not only genetic alterations but also 
epigenetic modification play a role in micro-VI. Various approaches are thus 
required to identify a new marker for micro-VI. 
Possible factors related to the pathogenesis of micro-VI in HCC 
In the studies on the molecular background of micro-VI in this thesis, tumor cells 
characteristics are studied but non-lesional liver parts are also included because by 
far the majority of HCC develops in a cirrhotic liver. This is in contrast with most 
other solid tumors which grow in an otherwise non-diseased organ as has been 
alluded to before. 
A cirrhotic liver is the result of long term chronic liver disease, usually 
associated with years of chronic inflammation due to variable causes and invariably 
involving longstanding cellular injury alternating with regeneration activity. Without 
effective clearance of the injurious cause fibrotic scarring will develop which 
ultimately can lead to cirrhosis. Cirrhosis is not a passive end-stage scar formation 
but represents a dynamic pathologic process characterized by progressive fibrosis 
due to excessive abnormal deposition of extracellular matrix, deformation of the 
lobular architecture and disruption of the normal vascular architecture following 
parenchymal cell death and vascular remodeling [Crawford and Burt, 2012]. This is 
the background liver in which HCC usually develops. 
One of the hallmarks of cancer is the ability of cancer cells to activate invasion 
and metastasis [Hanahan and Weinberg, 2011]. Vascular invasion is a complex 
process involving proliferation at the primary site, local invasion of tumor cells into 
adjacent tissue and intravasation of tumor cells. This process is part of the 
invasion-metastasis cascade in which vascular invasion is followed by 
extravasation, proliferation and colonization in the new site [Fidler, 2003; Talmadge 
and Fidler, 201 O]. This multistep process involves an interplay between cancer cells 
and its microenvironment which are involved in reciprocal signaling [Hanahan and 
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Weinberg, 2011]. Therefore, the process of vascular invasion can be studied from 
the perspective of the tumor but also from its microenvironment. With regard to 
HCC, the microenvironment has undergone several alterations due to processes 
involved in the development of cirrhosis. Two of such vital processes are 
angiogenesis and epithelial-mesenchymal transition (EMT). 
Angiogenesis and tumor vascularity: the relation with vascular invasion 
Angiogenesis and tumor vascularity are 2 different but closely associated entities. 
Tumor vascularity reflects the pattern of blood vessels in and around the tumor 
whereas angiogenesis relates to the process of blood vessel formation. 
Angiogenesis is defined as the formation of new blood vessels from 
pre-existing ones. Since cancers need blood supply for oxygen and nutrients to 
grow, cancer cells and cancer surrounding cells release various growth factors such 
as vascular endothelial growth factor (VEGF) to stimulate angiogenesis [Folkman, 
2002]. Such a pathological angiogenesis leads to changes of tumor vascularity. 
Normal liver receives a blood supply approximately 75% from the portal vein and 
the rest from the hepatic artery. In contrast, classical advanced HCCs receive their 
blood supply exclusively from abnormal arteries which lack the normal structure of 
portal tracts and accompanying veins and bile ducts. Therefore these tumor arteries 
are referred to as unpaired arteries. This is the reason why classical advanced 
HCCs are characterized by early enhancement in the arterial phase with washout in 
the portal phase during dynamic contrast-enhanced CT scan. On the other hand, 
early HCCs which contain portal tracts within the tumors do not only receive arterial 
blood flow from the unpaired arteries but also from pre-existing arteries and portal 
blood from the portal veins located within the intratumoral portal tracts [Nakashima 
et al., 1999; Kojiro, 2006]. 
So far, numerous studies have evaluated angiogenesis in HCCs [Fernandez et 
al., 2009; Sanz-Cameno et al. , 2010; Zhu et al. , 2011]. One of the most frequently 
chosen approaches is to measure the gene and/or protein expression of angiogenic 
growth factors and their receptors. Most studies indicate the existence of a 
correlation between tumor progression and increased angiogenic factors. Another 
common histological approach to evaluate the angiogenic status of HCCs is to 
measure the microvessel density (MVD) within the tumors. There is substantial 
evidence that supports the notion that MVD correlates with the expression of 
angiogenic growth factors and prognosis in some cancers [Uzzan et al., 2004; Des 
Guetz et al. , 2006; Rubatt et al., 2009; lordache et al. , 201 O]. In HCC, MVD is 
usually measured by counting CD34-positive sinusoidal endothelial cells within 
tumors [Tanigawa et al. , 1997]. Since tumor sinusoids are morphologically 
heterogeneous, definitions of MVD in HCC may vary. The variable definitions of 
MVD and the lack of standardized methods to count MVD are limitations of using 
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MVD as a measurement of angiogenesis. Nevertheless, within the mentioned 
limitations of MVD scoring as a measurement of angiogenic activity, MVD scoring 
has been applied in many studies that mainly focused on prognosis [Uzzan et al., 
2004; Des Guetz et al., 2006 ; Rubatt et al., 2009; lordache, 2010]. The majority of 
studies reports that high MVD is associated with poor prognosis after tumor 
resection or LT, although a few studies, including a previous study of our group, 
found a reverse correlation of high MVD with poor survival [Zeng et al. , 2010]. 
One of the predictive independent factors for poor prognosis is micro-VI, but no 
association has been reported between MVD and micro-VI [Zeng et al. , 201 O]. The 
results of chapter 3 are in line with these findings. We evaluated MVD according to 
a published method by others to enable comparisons with other publications and 
found no differences in MVD scores between HCCs with micro-VI and those without. 
Although a pathogenetic explanation for this lack of association between MVD and 
micro-VI is not available, it is conceivable that spatial differences of the 
microvessels involved in the 2 processes play a role. The microvessels evaluated in 
MVD scoring do not represent the microvessels involved in micro-VI. 
Histopathologically the latter is usually found in the vessels in the peritumoral 
stromal areas whereas MVD counts are predominantly performed in vascular hot 
spots at the peripheries of tumor nodules within the tumor boundaries. 
Pathological angiogenesis also takes place in the non-cancerous background 
liver as part of vascular remodeling in the process of liver fibrosis. Firstly, as a 
general process during liver wound healing, repetitive liver damage induces the 
production of several growth factors, such as VEGF, transforming growth factor 
(TGF)-131, fibroblast growth factor (FGF), which play a pro-angiogenic and/or 
pro-fibrogenic role in this process. Secondly, the progression of liver fibrosis 
increases vascular resistance in portal tracts and sinusoids and results in tissue 
hypoxia. Tissue hypoxia is a key switch to increase the expression of hypoxia 
inducible factor (HIF)-1a and VEGF [Fernandez et al., 2009; Pinzani et al., 2011]. 
This pathological angiogenesis creates abnormal vasculature in the liver, such as 
septal shunts: portal vein-to-terminal hepatic vein shunt; hepatic artery-to-terminal 
hepatic vein shunt, which leave hepatic parenchyma deprived of significant blood 
flow. Besides angiogenesis, repetitive liver damage also leads quiescent stellate 
cells into activated myofibroblasts. This activation of myofibroblasts induce 
increased collagen synthesis and decreased matrix metalloproteinases (MMPs) 
production followed by organ fibrosis. 
Fibrogenesis itself is thought to contribute to hepatocarcinogenesis, among 
others by paracrine interactions between stromal cells and tumorigenic cells [Zhang 
and Friedman, 2012]. Activated stellate cells not only produce growth factors such 
as hepatocyte growth factor (HGF), interleukin (IL)-6 and Wnt ligands that facilitate 
a growth friendly environment for proliferating hepatocytes but also promote 
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angiogenesis through secretion of Angiopoietin-1 [Friedman, 2008; Taura et al., 
2008]. 
HCC develops in the above described environment of active angiogenesis, 
fibrogenesis and an altered hemodynamic milieu which favor hypoxia 
[Hernandez-Gea et al., 2013]. During hepatocarcinogenesis increased need for 
oxygen and nutrients will increase angiogenic activity. According to recent insights 
tumor angiogenesis is not only regulated by cancer cells but also sustained by 
stromal cells in the tumor microenvironment [Hanahan and Coussens, 2012]. It is 
from this perspective that we performed the study in chapter 3 in which we 
investigated whether angiogenic activity in the tumor and in the adjacent tissue is 
associated with micro-VI. In an environment with active angiogenesis, neovessel 
formation may yield abnormal vessels, in particular leaky permeable vessels that 
are incompletely covered by pericytes which facilitate tumor intravasation [Hanahan 
and Coussens, 2012]. 
In chapter 3, we investigated the angiogenic profile of primary HCC and 
peritumoral cirrhotic but non-cancerous liver in relation to the presence or absence 
of micro-VI. We found increased expression of placental growth factor (PIGF) in the 
peritumoral tissue of micro-VI positive HCC as compared with the peritumoral tissue 
of the micro-VI negative HCC. In addition, in the peritumoral tissue of the micro-VI 
positive HCC, PIGF and vascular endothelial growth factor receptor (VEGFR)-1 
expression was upregulated compared with its corresponding HCC. In the micro-VI 
negative group this discrepancy was not observed. These findings indicate the 
significance of the changes in the micoenvironment of the tumor which is the 
location of micro-VI in HCC. 
PIGF stimulates endothelial cell growth, survival and migration in pathological 
condition but PIGF is not involved in normal vascular development and 
maintenance. PIGF can potentiate the angiogenic effect of VEGF mediated 
signaling by binding to VEGFR-1 and displacement of VEGF from VEGFR-1 to 
VEGFR-2 [Carmeliet et al., 2001]. Overexpression of PIGF results in increased 
tumor vascularization consisting of abnormal blood vessels with incomplete 
coverage by pericytes and an irregular basement membrane [Adini et al., 2002] 
whereas blockage of PIGF inhibits tumor vessel arterialization and abnormalization 
as observed in experimental HCC. The latter process also impedes tumor growth 
without significant effects on vessel density [Van de Veire S et al. , 2010]. Therefore 
it is conceivable that the peritumoral profile of increased PIGF and VEGFR-1 gene 
expression may stimulate generation of abnormal vessels that are permissive to 
tumor intravasation due to its abnormal architecture. Recently, Heindryckx et al 
demonstrated in an animal model of HCC that anti-PIGF antibody can inhibit 
neovascularisation and normalize the remaining blood vessels. The authors 
suggested that this treatment can reduce the prometastatic potential of HCC 
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[Heindryckx et al, 2013]. Development of new drugs can follow this strategy of 
normalizing the abnormal structures within the tumor microenvironment [Jain, 
2013]. 
Epithelial-mesenchymal transition and microvascular invasion 
EMT was originally defined by the formation of mesenchymal cells from 
epithelial cells in a physiological embryonic process, and has now been linked to 
fibrosis and cancer progression. According to the involvement of EMT in these three 
different biological settings, EMT was classified into three subtypes by Kalluri and 
Weinberg [Kalluri and Weinberg, 2009]. 
Type 1 EMT is observed in various phases of embryonal development and 
organ maturation, and causes neither fibrosis nor uncontrolled cancer invasion. For 
instance, the primitive epithelium gives rise to primary mesenchyme through the 
formation of primitive streak generated in the epiblast layer [Hay, 2005; Lim and 
Thiery, 2012]. 
Type 2 EMT is associated with wound healing, tissue regeneration, and organ 
fibrosis, which are presumably the consequence of inflammation. It has been shown 
that some activated fibroblasts/myofibroblasts are derived from pre-exsiting 
epithelium via EMT, and are able to produce collagen-rich extracellular matrix in the 
development of organ fibrosis [Carew et al. , 2012]. A big difference between Type 1 
and Type 2 EMT is that type 2 EMT is pathogenic and can cause organ dysfunction 
as long as the causes of inflammation or tissue damage are not removed. 
Type 3 EMT occurs in the process of epithelial cancer progression in which 
carcinoma cells lose their epithelial characteristics and acquire mesenchymal 
features in order to obtain the ability to invade and to disseminate [Meng and Wu, 
2012]. Due to the increased motility, these cells are able to detach from the 
basement membrane, invade the tumor stroma and blood vessel to enter the 
circulation. To metastasize, the cancer cells have to exit the blood vessels to form 
micro- and macro metastases at suitable sites. The latter steps may require a 
reverse process, mesenchymal-epithelial transition (MET), to enable the cancer 
cells to colonize and grow at the new sites [Meng and Wu, 2012]. This complex and 
multistage process does not only induce invasiveness, but the acquisition of 
mesenchymal cell properties goes along with survival enhancing capabilities by 
evasion of apoptosis, cellular senescence, dependence on oncogenes and immune 
defense [Tiwari et al., 2012]. Of note, these competences are in line with the recent 
insight that carcinoma cells that undergo EMT contain cancer stem cell (CSC) 
properties [Tiwari et al., 2012; Meng and Wu, 2012]. EMT and cancer progression is 
orchestrated by cascades of signaling pathways involving a complex cross talk 
between these pathways. In short, following proper stimulatory signals several 
factors such as TGFl3, Wnt, insulin-like growth factor (IGF), FGF, HGF, 
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platelet-derived growth factor (PDGF) and epithelial growth factor (EGF) may 
activate signaling pathways that result in expression of several EMT inducing 
transcriptional factors including Snail -1, Snail-2, Zeb-1, Zeb-2 and Twist [Tiwari et 
al., 2012]. Another group of important players in this EMT orchestra is the 
micro-RNAs. Several micro-RNAs are involved in EMT by positively or negatively 
influencing the expression of ligands, receptors, signaling pathways and 
transcription factors [Tiwari et al. , 2012; Meng and Wu, 2012]. 
Transformation of epithelial cell phenotype into a mesenchymal one is 
characterized by loss of epithelial cell markers, e.g. E-cadherin, cytokeratins and 
acquisition of mesenchymal ones such as N-cadherin, a5j36 integrin and nuclear 
13-catenin [Tiwari et al. , 2012]. The loss of E-cadherin expression by carcinoma cells 
is one of the effects of EMT and an initial step of invasion and it has been reported 
in several types of invasive carcinomas, including HCC [Thiery et al. , 2009]. 
E-cadherin is a vital cell-to-cell adhesion molecule that strengthens the epithelial 
cells in cell sheets and maintains the cellular quiescence in these sheets 
[Schmalhofer et al. , 2009]. Loss of E-cadherin may result from gene mutation 
leading to production of a defective protein, an aberrant posttranslational 
modification or increased proteolysis, regulated by several of the abovementioned 
pathways [Tiwari et al. , 2012]. In HCC, increased expression of the transcription 
factors Twist and Snail, in association with repression of E-cadherin and the 
presence of a CSC population has been reported [Yang et al. , 2004; Cano et al. , 
2000]. In HCC, cytokeratin (CK) 19 and epithelial cell adhesion molecule (EpCAM) 
are regarded as CSC markers since CSCs share their markers with somatic stem 
cells of the original tissue in the different types of cancers [Yamashita et al., 2009; 
Kim et al. , 2011]. 
In chapter 3, we found decreased E-cadherin expression within the micro-VI 
positive HCC at both gene and protein levels compared with the micro-VI negative 
ones. However, we did not find a correlation between the existence of micro-VI and 
the expression of the hepatic stem-cell markers CK19 or EpCAM in HCC. In the 
non-cancerous adjacent liver, both CK19 and EpCAM are expressed by bile 
ductules, which possibly harbor bipotent liver progenitor/stem cells, [Schmelzer et al, 
2006; Zhang et al. , 2008; Gouw et al., 2011]. 
The relationship between EMT and CSC are not fully understood. One possible 
link is the fact that the cells that undergo EMT contain CSC properties, and such 
cells that possess tumorigenicity may play a critical role in the proliferation of cancer 
cells at the distant site as well as in the progression of cancer at the primary site 
during the early phase [Scheel et al., 2012] . Other factors that have been identified 
recently as positive inductors of EMT and micro-VI in HCC are stress-activated 
protein kinase (SAPK) interacting protein 1 (SIN1) and sirtuin 2 (SIRT2), each 
operating through different pathways. Xu et al showed a significant correlation 
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between increased SIN1 expression and poor prognosis and clinicopathological 
parameters related to prognosis, such as tumor numbers and venous invasion. 
Moreover, it has been shown that SIN1 facilitates EMT through Akt activation 
followed by the upregulation of Snail [Xu et al., 2013]. Chen et al also reported that 
the upregulation of SI RT2 was significantly correlated with poor overall survival and 
micro-VI, and demonstrated that SIRT2 expression levels are associated with 
mortality and invasiveness of HCC cells and with EMT through protein kinase 
B/glycogen synthase kinase-3�/�-catenin signaling [Chen et al., 2013]. Autophagy, 
which is an intracellular process for the degradation of unnecessary cellular 
components, has also been reported to positively influence invasion in HCC through 
stimulation of EMT via induction of the TGF�/Smad pathway [Li et al. , 2013]. 
Tumor characteristics that influence microvascular invasion 
Tumor characteristics usually include the gross appearance, size, the number of 
tumor nodules and the cellular morphology. All these different phenotypic features 
have been found to be associated with micro-VI as reviewed in chapter 2. The 
gross appearance of HCC tumor nodules is predominantly studied and applied as a 
predictive factor for micro-VI in Asian countries. The Liver Cancer Study Group of 
Japan classified nodular HCC into 3 subtypes depending on the contours of the 
nodules and based on the macroscopic appearance of the resected specimens. 
The simple nodular type is a distinct nodule with a smooth outline which frequently 
consists of a fibrous capsule. When such a nodule shows extranodular growth it 
represents the second type. The third type consists of coalescing nodules, the 
confluent multinodular type [Liver Cancer Study Group of Japan, 2009]. The latter 
type has the strongest association with micro-VI [Hui et al, 2000; Sumie et al., 
2008]. 
Several studies reviewed in chapter 2 showed variable results on the 
association between micro-VI with these tumor characteristics but in general an 
increase in the prevalence of micro-VI parallels increases in tumor size, number of 
tumor nodules and higher tumor grade. In our study we found an association 
between micro-VI and higher tumor grade (chapter 3) but not with the other tumor 
characteristics. The variable results may be explained by factors such as sample 
size of the study, the robustness of the method to detect micro-VI and the grading of 
the tumor. However, all mentioned tumor characteristics are in fact surrogate 
markers of the growth potential of the tumor. Size, contours and number of nodules 
reflect the mode and pace of tumor growth whereas tumor grading identifies an 
aggressive or less aggressive cell population. Higher grade tumors consist of less 
differentiated tumor cells associated with more aggressive behavior, hence 
increasing the chances of invasion. Apart from assessment of histomorphological 
features based on the HE staining that is routinely applied for tumor grading, 
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identification of other cellular features, such as CSC characteristics can be done by 
specific immunophenotyping . The presence of CSC populations in HCC has been 
reported in a number of studies, in which they were identified by various types of 
cell surface markers , e .g . ,  CK19 , CD133 , CD90 , EpCAM ,  and CD13 . [Yin et al. , 
2007;  Yang et al . ,  2008; Yamashita et al. , 2009 ; Haraguchi et al. , 2010]. C K19 is 
regarded as a marker for bipotent hepatic progenitor/stem cells which have the 
capability to differentiate to either hepatocytes or cholangiocytes. Among these 
markers , immunophenotyping using EpCAM and CK19 have been well studied , 
probably because antibodies to detect EpCAM and CK19 are robust and easily 
obtained. The presence of both EpCAM positive and CK19 positive tumor cells in 
HCC is associated with vascular invasion and poor prognosis and is thought to be 
associated with their CSC features. CSC are characterized by the following abilities: 
self renewal with or without differentiation ;  high tumorigenicity ; and 
chemoresistance, all of which are functions that increase the capacity for tumor 
recurrence and/or metastasis . 
Among patients with small HCC, the prognostic role of micro-VI is still 
controversial . Recently Shindoh et al have reported that the presence of micro-VI 
does not affect patients ' prognosis in HCC up to 2cm [Shindoh et al . ,  2013] .  On the 
other hand , Nakashima et al reported a higher frequency of micro-VI in confluent 
multinodular type and single nodular type with extranodular growth than in single 
nodular type among HCCs less than 3cm [Nakashima et al. , 2003] .  It is possible 
that there are tumor subgroups that are likely to have micro-VI and early recurrence 
due to a different biological behavior e.g. the confluent multinodular type HCC . This 
type is characterized by a lack of capsule which may faciltate invasion. This 
speculation requires further studies regarding the relationship between gross type 
and growth behaviour , especially in small HCCs. 
The role of ductular reaction in microvascular invasion 
The results of the studies in chapter 3 indicate the importance of the peritumoral 
compartment. In chapter 4 thus we performed further investigations in this area. 
Using laser microdissection we isolated the peritumoral fibrous septa (PT septa) 
and perinodular cirrhotic septa collected from areas distant from the tumor (D septa) . 
Gene expression studies of genes related to angiogenesis , EMT and liver 
progenitor cells such as EpCAM and C K19 revealed a significant decrease of 
EpCAM and E-cadherin in PT septa of micro-VI positive HCC septa compared to its 
D-septa counterpart. This difference was not found in the micro-VI negative HCC. 
Since both EpCAM and E-cadherin can only be expressed by ductular cells as 
these are the only epithelial structures in the fibrous septa , we assumed that these 
different gene expression levels of EpCAM and E-cadherin may result from the 
decreased number of ductules in PT septa which would be in accordance with the 
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results of Lennerz et al [Lennerz et al., 2011 ]. Semiquantitative scoring of the 
ductular structures in PT septa and D septa using EpCAM immunohistochemistry 
( chapter 4) confirmed the gene expression results that there is a decrease of 
EpCAM positive ductules in micro-VI positive PT septa compared with the 
corresponding D septa, although the difference did not reach statistical significance 
(P=0.09) which was probably due to the small sample size of 11 samples. To 
validate the results of this first cohort, a similar quantitative study was performed on 
a second cohort of 25 samples labeled with EpCAM and scored without prior 
knowledge of the status of micro-VI. A significant lower numbers of EpCAM positive 
ductules was found in the PT septa of micro-VI positive HCC in comparison with the 
corresponding D septa (P=0.002). This pattern was not found in the micro-VI 
negative HCC. This finding is of potential value to be applied as a predictive factor 
for micro-VI in HCC. A similar quantification can be applied in biopsy specimens 
containing sufficient peritumoral septal areas and fibrous septa distant from the 
tumor. Robust validation studies are however necessary prior to implementation of 
this analysis in daily clinical practice. 
Ductular reaction is a reactive process which arises in diseased livers, at the 
interface of portal and parenchymal compartments during liver damage and 
regeneration [Gouw et al., Hepatology 2011]. Recently ductular reaction has been 
found to play a role in the transition of dysplastic nodules in cirrhotic livers into HCC. 
Lennerz et al documented diminishing numbers of CK19 positive perinodular 
ductular structures in parallel with progression of intranodular hepatocytes into HCC. 
The disappearance of the ductular cells was neither due to necrosis nor apoptosis. 
Concurrent with these changes there was an increase of cells expressing EMT 
markers [Lennerz et al., 2011]. These findings are compatible with EMT as part of 
cancer progression as has been addressed in the previous paragraphs. The fact 
that perinodular structures undergo such profound changes during 
hepatocarcinogenesis corroborates our findings in chapters 3 and 4 that the 
peritumoral tissue, as part of the tumor microenvironment plays an important role in 
HCC progression which includes micro-VI. 
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Despite the recent progress in the management of HCC , the majority of HCC is 
diagnosed at the intermediate or advanced stage [EASL, 2012] representing the 
stages of BCLC- 8 ,  C ,  or more . Patients within these categories are not eligible for 
potentially curative radical therapies. Therefore , the development of effective 
systemic therapy for HCC is needed. As mentioned in the general introduction part , 
sorafenib is the first ,  and so far the only systemic agent with proven survival benefit 
among BCLC-C patients in several large randomized controlled trials (RCTs) [Llovet 
et al. , 2008; Cheng et al. 2009] .  This clinical success of sorafenib in HCC evoked a 
trend of molecular targeted drugs for HCC. Dozens of molecular targeted drugs for 
HCC are currently being assessed in clinical trials , which are broadly classified as 
either monoclonal antibody (MAb) or small molecule tyrosine kinase inhibitors (TKI) 
[Villanueva and Llovet, 2011]. MAbs target specific antigens found on the cell 
surface which are closely related to tumor progression. TKls interfere with the 
enzymatic activity of the targeted tyrosine kinase. For instance , Sorafenib inhibits 
several receptor tyrosine kinases , such as VEGFR and platelet -derived growth 
factor receptor (P DGFR) located on the cell membrane , and intracellular kinase 
pathways. 
The role of interferon therapy 
By the end of 2012 after the initial success of sorafenib , 4 new molecular targeted 
drugs: sunitinib ; brivanib ; linifanib and erlotinib , were assessed by phase 3 clinical 
trials , and 4 more drugs: regorafenib ; everolimus ; ramuciru mab ; tivantinib , are now 
in phase 3 clinical trials [Villanueva ,  2013]. Notably , the main targets of 5 out of 
these 8 new drugs include VEGFR , P DGFR and Tie-2 which is the specific receptor 
for Angiopoietins . Thus angiogenesis is regarded as an important target for HCC 
therapy. However , 4 drugs that have already been evaluated did not show positive 
results and 3 of the 4 were those targeting these angiogenesis-related tyrosine 
kinase receptors. This fact requires a reconsideration of the strategy of 
molecular-targeted cancer therapy. One possible approach to be considered is a 
molecular approach of patient selection. For instance , transtuzumab which inhibits 
HER2/neu receptor is administered to patients with HER2-positive breast cancer 
[Slamon et al . ,  2001] ,  and cetuximab , which interferes with EGFR , to those with 
EGFR- expressing colorectal cancer [Cunningham et al. , 2004]. In addition , during 
clinical studies with cetuximab , it was shown that the absence of the K-ras mutation 
is a favorable factor for the response [Karapetis et al. , 2008] . Similary , it is known 
that gefitinib and erlotinib which also inhibit EGFR are effective in patients with 
EGFR-mutated lung adenocarcinoma [Paez et al. , 2004] .  Another approach is to 
target other molecular players , e.g . mutated genes that are critically involved in 
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hepatocarcinogenesis. For instance, an abnormal translocation between 
chromosome 9 and 22 and the consequent continuously activated Bcr-Abl tyrosine 
kinase underlie the development of chronic myelogenous leukemia (CML). 
Therefore, imatinib which inhibits Bcr-Abl tyrosine kinase can show dramatic effects 
on patients with CML [Goldman and Melo, 2003]. Although such a chromosomal 
translocation is rare among malignant epithelial neoplasms, EML4-ALK fusion was 
detected in some lung adenocarcinoma [Soda et al. , 2007]. Following this novel 
finding, anaplastic lymphoma kinase (ALK) inhibitor crizotinib was readily approved 
as a first line drug for patients with ALK positive lung cancer [Shaw et al., 2011]. 
Patients selection seems important in the success of molecular-targeted drug. Such 
an approach for HCC requires discovery and validation of such drugs. 
Apart from molecular targeted drugs, conventional anti-cancer drugs for HCC 
also should be evaluated as potential drugs that might give some add-on effects to 
sorafenib. Although there are few drugs that have shown such an effect against 
HCC, IFNs might be candidates. IFNs are cytokines that are produced by host cells, 
such as leukocytes, in response to inflammation. Since IFNs possess 
antiproliferative activity, IFN therapy is used to treat patients with malignant 
melanoma, acquired immunodeficiency syndrome-related Kaposi's sarcoma, and 
some hematopoietic malignancie [Garbe et al., 2011; Pestka et al., 1987; Jonasch 
and Haluska, 2001]. In the field of liver disease, IFNs are commonly used to treat 
patients with chronic viral hepatitis because of their antiviral activity and 
immunoregulatory effect. Especially, for the patients with hepatitis C infection, 
combination therapy of pegylated IFN (PEG-IFN) and ribavirin, with or without 
telaprevir, is standard [Ghany et al. , 2009; Jacobson et al. , 2011]. Two decades ago 
it was shown by RCT conducted by Lai et al for the first time that IFN-a therapy can 
prolong patient survival in inoperable HCC [Lai et al. , 1993]. In addition, systemic 
IFN therapy can improve survival in advanced HCC in combination with hepatic 
intraarterial cisplatin infusion compared with hepatic intraarterial infusion (HAI) 
monotherapy [Chung et al. , 2000]. Some Japanese researchers also showed 
effects of combination therapy of systemic IFN administration and hepatic 
intraarterial 5-fluorouracil (5-FU) infusion [Obi et al., 2006], and RCTs regarding IFN 
therapy combined with HAI are ongoing. 
Thus IFNs have been used for patients with diseased liver, and have potential 
benefits in patients with HCC. It is worthwhile to study the add-on effect of IFNs in 
HCC treated with sorafenib. 
In chapter 5 and 6, we investigated the antitumor effects of PEG-IFNs with or 
without sorafenib on HCC cells in vitro and in vivo. Firstly, we found that PEG-IFN 
monotherapy can decrease tumor progression in vivo and is more effective than 
non-pegylated forms of IFN. Secondly, although the effects of therapy differed in 
cell lines, combination therapy of sorafenib and PEG-IFN can induce better effects 
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than monotherapy. It is also believed that IFNs have chemopreventive effects 
against the development of HCC to some degree. However, two large RCTs, which 
were conducted by the HAL T-C and EPIC groups, failed to prove that long term 
maintenance PEG-IFN therapy can reduce the incidence of HCC [Di Bisceglie et al. , 
2008; Lok et al., 2009; Bruix et al., 2011]. On the other hand, there are several 
reports that showed survival benefit or the reduction of recurrent HCC of IFN 
therapy after initial therapy [Sakaguchi et al., 2005; Nishiguchi et al. , 2005]. There 
are also some reports that showed IFN therapy reduced the occurrence of HCC 
among particular patient groups, e.c. patients with HBV infection or those who 
underwent curative resection of HBV-related HCC [Miyake et al. , 2009; Qu et al. ,  
201 O]. Again, patient selection is crucial for the success of IFN therapy. In 2009, 
three different groups reported that genetic variation in IL28B encoding IFN-A-3 is 
associated with response to PEG-IFN and ribavirin therapy for chronic HCV 
infection [Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009]. The 




In this thesis, we performed studies on two issues that influence the prognosis of 
HCC, micro-VI (part I) and sensitivity of HCC cells to IFN (part II). In chapter 2 we 
reviewed the current status of methods to predict micro-VI preoperatively and 
concluded that currently there is no reliable method to predict micro-VI before 
surgery. The studies in chapters 3 and 4 were both performed to establish a profile 
of micro-VI positive HCC that may yield a predictive factor of micro-VI. Results of 
these studies indicated the importance of peritumoral tissue as a compartment that 
contains changes related with micro-VI. This was represented partly in altered 
angiogenic characteristics as witnessed by upregulation of PIGF and VEGFR-1 
expression and partly in decreased numbers of ductular structures that probably 
undergo phenotype switching during progression of HCC as part of cancer related 
EMT. The decreasing numbers of ductules may serve as a predictive factor of 
micro-VI in tumor biopsies. 
The studies in part II evaluated PEG-IFNs as a promising drug combined with 
sorafenib. As 70% to 80% of patients with HCC are diagnosed at the stage where 
there is no curative treatment option, effective systemic therapy options are still 
sought for. In chapter 5 and 6, we demonstrated the anti-proliferative effect of 
PEG-IFNs with or without sorafenib in various HCC cell lines. Sensitivity to each 
combination varied leading us to conclude that molecular tumor profiling will be 
necessary to improve the sensitivity of therapies based on the matching of the 
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Chapter 2 
It is well known that hepatocellular carcinoma (HCC) commonly involves the local 
branches of portal and/or hepatic veins and causes a tumor thrombus even at a 
relatively early stage. Vascular invasion is classified as macrovascular invasion, 
which is grossly recognizable (mostly in large to medium vessels), or microvascular 
invasion (MVI), which can be identified only by microscopic observation (mainly in 
small vessels such as portal vein branches in portal tracts, central veins in 
noncancerous liver tissue, and venous vessels in the tumor capsule and/or 
noncapsular fibrous septa). 
Although macroscopic vascular invasion in major vessels (and satellite 
nodules) is known to be a marker of poor outcomes after liver transplantation (LT) 
for HCC and is regarded as a contraindication for LT, the significance of MVI as a 
predictor of poor outcomes is still controversial. The controversy concerns the 
extent to which MVI (if it is identifiable before surgery) is a contraindication for LT, 
even though we know that only a minority of patients with MVI will experience HCC 
recurrence. 
MATERIALS AND METHODS 
We searched the MEDLINE database (2002-2010) to determine the significance of 
MVI to the outcomes of LT for HCC; we used the keywords hepatocellular 
carcinoma, HCC, microvascular invasion, liver transplantation, and liver resection. 
We also performed a full manual search of the bibliographies of selected 
publications and included 4 additional publications from earlier years. Publications 
were included if they contained data on MVI and its relationship with tumor 
characteristics and/or prognostic data. The search resulted in a total of 48 relevant 
publications. 
The publications were then ranked according to the classification proposed by 
the Oxford Centre for Evidenced-Based Medicine. 
RESULTS 
Question 1 .  Is There Any Correlation Between MVI and Tumor 
Characteristics? 
Many published studies have found that the presence of MVI is closely related to 
the tumor size, number, and histological grade [1-8] (Table1 ). Esnaola et al. [1] 
studied MVI in 245 HCC patients who underwent surgical resection and fulfilled the 
Milan criteria, and they found that 33% of their patients had histopathological 
evidence of MVI. Patients with tumors larger than 4 cm were 3 times more likely to 
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have MVI than those with tumors measuring 4 cm or less. Patients with poorly 
differentiated or undifferentiated tumors were 6 times more likely to have MVI than 
those with well-differentiated tumors. In comparison with patients with 
well-differentiated tumors, patients with multiple tumors were 2 times more likely to 
have MVI, and patients with moderately differentiated tumors were 2.6 times more 
likely to have MVI. Others have also reported that the presence of MVI is closely 
related to a larger tumor size and a lower histological grade (Table 1 ). 
Table 1 .  MVI and Tumor Characteristics 
Size (cm) Number Histological g rade 
Esnaola et al. [ 1 ]  >4 NS Moderately to poorly d ifferentiated 
Shah et al. [2] >3.8 >3 NS 
Parfitt et al. [3] >3 >3 Moderately to poorly differentiated 
Lohe et al. [4] >5 NS Moderately to poorly d ifferentiated 
Jonas et al. [5] 3~5 2~3 Moderately to poorly d ifferentiated 
Bhattachrijya et al. [6] >4 3 Moderately to poorly d ifferentiated 
Shirabe et al. [7] >2-4 multiple Moderately to poorly d ifferentiated 
Pawlik et al. [8] >5 multiple High  grade (moderately to poorly differentiated) 
Relationship Between MVI and the Gross Type 
The Liver Cancer Study Group of Japan proposed a gross classification scheme for 
resected HCC in 1997 [9], and it has been widely used in Japan. In the Liver Cancer 
Study Group of Japan classification scheme, nodular tumors are divided into the 
following subclasses: (1) a simple nodular type (a distinctly nodular tumor that 
frequently has a capsule), (2) a simple nodular type with extranodular growth (a 
single nodular tumor with varying degrees of tumor growth beyond the tumor 
capsule), and (3) a confluent multinodular type (a confluence of several minute to 
small nodules; see Fig. 1 ). 
Since the Liver Cancer Study Group of Japan classification was proposed, it 
has been reported that the rate of MVI is closely related to the gross type.10-12 In a 
study of 65 resected HCCs, Hui et al.[10] reported that the MVI rates were 17% for 
the simple nodular type, 25% for the simple nodular type with extranodular growth, 
and 53% for the confluent multinodular type (P < 0.03 for the simple nodular type 
versus the simple nodular type with extranodular growth, P < 0.02 for the simple 
nodular type versus the confluent multinodular type). In a study of 110 resected 
HCCs, Sumie et al. [11] also reported a significantly higher prevalence of MVI for the 
simple nodular type with extranodular growth (72%) and the confluent multinodular 
type (84%) in comparison with the simple nodular type (20%, P < 0.001). They 
stressed that the gross classification of the simple nodular type with extranodular 
growth or the confluent multinodular type was an independent predictor of MVI in 




In a large series, Kaibori et al. [13] confirmed that a large tumor size was a 
preoperative predictor of MVI. Unfortunately, the MVI group included patients with 
macrovascular invasion. 
Similar results were obtained by Shirabe et al. [14] for patients undergoing living 
donor LT. An independent predictor of poor recurrence-free survival was 
preoperative type 3 HCC (a contiguous multinodular type with a large tumor size, a 
poor histological grade, and a high incidence of MVI and multiple tumors). 
Notably, tumor cell invasion of the portal vein is observed in 27% of cases with 
early HCC (ie, up to 2 cm) of a distinctly nodular type, and minute intrahepatic 
metastases in the vicinity of the tumor are present in 10%. These features are not 
observed in small HCCs of an indistinct nodular type [15]. Margin distinct 
0 0 � Simple nodular type Simple nodular type Confluent with multinodular type e:,,,.iranodular growth 
Figure 1 . Gross classification scheme for HCC by the Liver Cancer Study Group of Japan. Reprinted with 
permissio n from General Rules for the Clinical and Pathological Study of Primary Liver Cancer [9]. 
Copyright 201 0, Kanehara & Co. ,  Ltd. Tokyo, Japan. 
Comment 
The majority of studies have shown a close correlation between MVI and tumor 
characteristics. Increases in the prevalence of MVI parallel increases in the tumor 
size, number, histological grade, and gross features. The last are based on the 
Japanese gross classification system, which is not widely applied in Western 
countries [9]. 
In summary, because MVI is a microscopic feature that can be assessed only 
on the tissue level, MVI cannot be definitely confirmed during the pre-LT stage. 
However, to a certain extent, the likelihood of the presence or absence of MVI can 
be predicted during the pre-LT stage on the basis of the tumor size and number, 
which are assessable with imaging modalities. The histological grade is an 
additional predictive parameter on the tissue level that can be assessed by pre-LT 
biopsy, whereas the gross features can be examined only after LT. After LT, MVI is 
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valuable because of its association with the tumor recurrence rate, which we 
address later . 
Notably, 2 studies have reported that the tumor growth rate or the tumor doubling 
time is predictive of tumor recurrence after LT [16, 17]. The association between 
these features and MVI has not been studied, but they merit further attention as 
additional important tumor characteristics that might be related to MVI . 
Question 2. Are There Any Imaging Modalities for Detecting MVI ? 
Although macrovascular invasion can be preoperatively detected by conventional 
imaging modalities such as computed tomography (CT), magnetic resonance 
imaging (MRI), and ultrasound, the preoperative imaging determination of MVI is 
impossible because MVI is a microscopic parameter . 
However, Kornberg et al. [18] reported that increased [ 1 8F]fludeoxyglucose 
([
1 8F]FDG) uptake du ring positron emission tomography (PET) is predictive of MVI 
and tumor recurrence after LT. In their study, 42 patients who underwent LT for 
HCC were examined with P ET preoperatively ; 16  had positive PET scans, whereas 
26 showed no increase in their fludeoxyglucose (FDG) uptake . Five of 6 patients 
with a poor tumor grade had a PET-positive status, and 14 of 17 patients with MVI 
(82.4%) had a positive P ET finding. Eight of the 16 patients with a PET-positive 
status (50%) developed HCC recurrence, whereas only 1 of the 26 PET-negative 
patients did (P < 0.001 ). Furthermore, the PET-negative patients had a significantly 
better 3-year recurrence-free survival rate than the PET-positive patients . It has 
been shown that well-differentiated HCC cells exhibit an [ 1 8F]FDG metabolism 
similar to that of normal liver cells, whereas poorly differentiated tumor cells do not . 
The authors hypothesized that PET scan patterns may have a clinically relevant 
correlation with the presence of MVI because of the c lose relationship between MVI 
and a poor tumor grade . However, there is no evidence that FDG uptake is an 
independent predictor . 
More recently, positive FDG PET results at the time of listing for LT have been 
found to reflect tumor behavior and to be strongly associated with dropout due to 
tumor progression. PET could be proposed as an additional tool for the pre-LT 
assessment of candidates with HCC [19]. Hui et al . [1 0] tested whether the 
Japanese gross classification system9 could be used with preoperative dynamic CT 
(10-mm interval slices). They found that classifications based on CT findings and 
classifications based on macroscopic observations were concurrent for 46% of their 
patients. The simple nodular type, the simple nodular type with extranodular growth, 





So far, conventional imaging modalities have been ineffective for the preoperative 
detection of MVI. Only 1 study has shown the potential usefulness of PET scans in 
the prediction of MVI [18]. The preliminary results of an MRI study have shown that 
the MRI features of HCC do not predict MVI in the transplanted liver [20]. Although 
the gross classification scheme of the Liver Cancer Study Group of Japan9 is not 
popular in Western countries, because of the 40% identity rate for dynamic CT 
findings and the confluent multinodular type (for which there is an MVI prevalence 
rate of 53%-84%), gross subclassification by dynamic CT merits further study.11 
This can also be recommended because of the potential value of PET scans and 
MVI and the scarcity of data. 
Question 3. Are There Any Biochemical Markers for Predicting MVI? 
Des-gamma-carboxyprothrombin (DCP), also known as protein induced by vitamin 
K absence or antagonist II, is an abnormal form of prothrombin, and it has been 
used as a good diagnostic biomarker for HCC, particularly in Japan [21-23]. It has 
been reported that high serum levels of DCP reflect the invasiveness of HCC and 
are related to the histological vascular invasion of cancer cells. Koike et al. [22] 
prospectively studied 227 patients with HCC who did not show portal venous 
invasion and who received percutaneous ethanol injection therapy and/or 
microwave coagulation therapy at the time of their first admission. The patients 
were followed for a mean of 19 months with ultrasonography every 3 months, with 
CT scans every 6 months, and with measurements of biochemical parameters such 
as DCP and alpha-fetoprotein (AFP) every month. A multivariate Cox regression 
analysis of various factors showing significant correlations with the later 
development of portal venous invasion revealed that the DCP level was the 
strongest predisposing factor (P < 0.001 ). Shirabe et al.[7] studied 218 patients who 
had tumors without any extrahepatic metastases or vascular invasion (according to 
their preoperative evaluations) and underwent HCC resection. They found that the 
preoperative DCP level for the patients with MVI was significantly higher than the 
level for the patients without MVI (P < 0.049), and it was an independent predictor of 
MVI. In another recent study [14], the same authors showed that a preoperative 
serum DCP level exceeding 300 mAU/m was an independent predictor of poor 
recurrence-free survival in patients undergoing living donor LT. 
In a study of 144 HCC patients treated with living donor LT, Fujiki et al. [23] 
reported that the incidence of MVI was significantly higher for patients with a DCP 
level > 400 mAU/mL versus patients with a DCP level s 400 AU/ml. 
Eguchi et al. [21] studied 179 patients without macroscopic venous invasion 
who underwent curative resection for HCC. High preoperative levels of DCP and the 
gross appearance of the tumor appeared to be strong predictive factors for MVI, 
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even for tumors less than 5 cm in size. The gross features that were associated with 
MVI were extranodular growth, m ultinodularity, and infiltrative growth . 
The value of DCP in predicting MVI recurrence should not be compared to the 
value of DCP in predicting HCC occurrence. Ster ling et al . [24] concluded that mild 
to moderate elevations of the total AFP and DCP levels (but not the AFP-L3 levels) 
occur frequently in patients with chronic hepatitis C and advanced cirrhosis, b ut they 
are related to factors other than HCC and are poor indicators of HCC. They 
recommended that these biomarkers not be part of routine surveillance protocols. 
An increase in the AFP level greater than 15 µg/L/month during the wait for LT 
has been shown to be the most relevant preoperative prognostic factor for low 
overall and disease-free s urvival. An elevated AFP level was shown to be a 
predictor of a lower recurrence-free survival rate in a large series of 283 transplant 
patients (odds ratio = 2.88, 95% Cl = 1 .43-5 .80, P = 0 .003).25 An increase in the 
AFP level could be a preoperative pathological marker of tumor aggressiveness [26]. 
In the past 2 decades, attempts have been made to detect circulating tumor cells in 
the peripheral blood of HCC patients through the examination of tumor-related 
markers [27-29] .  However, the results are still only probab le because of the lack of 
truly reliable HCC-related markers . 
It is likely that new blood markers will be proposed in the future . Recently, the 
angiopoietin 2 level has been shown to be a predictor of tumor invasiveness in 
patients with HCC [30]. 
Comment 
The significance of a high serum DCP level as a good biomarker for predicting MVI 
has been suggested mostly in Japanese studies . Hence, an international, 
multicenter study is required to assess the precise predictive value of DCP in a 
broader group of HCC populations . 
Furthermore, other predictive parameters should be evaluated . Reports on 
factors in HCC tissue that are associated with MVI at protein and gene expression 
levels are emerging . Liver-intestine cadherin has been reported to be correlated 
with MVI in hepatitis 8 virus-related HCC [31]. A genetic signature of microvascular 
invasiveness has a lso been reported in a genome-wide analysis [32] .  The potential 
of these factors as future biomarkers merits further studies. 
The use of an artificial neural network to predict the tumor grade and MVI on 
the basis of noninvasive variables is notable [33]. An artificial neural network and 
logistic regression models were based on a training group of 175 randomly chosen 
patients and were tested on 75 patients . In the testing group, the artificial neural 
network correctly identified 93 .3% of the tumor grades (k = 0 .81) and 91 % of the 
MVI cases (k = 0.73). The logistic models correctly identified 81 % of the tumor 
grades (k = 0 .55) and 85% of the MVI cases (k = 0 .57). In this study, many clinical, 
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radiological, and pathological factors were taken into account, but the DCP level 
and the body mass index were not. Surprisingly, in a study of 1 38 consecutive 
patients who underwent surgery at Columbia University Medical Center from 
January 1 ,  2002 to January 9, 2008, Siegel et al. [34] found that patients with a body 
mass index > 30 kg/m2 had MVI at rate of 40%, whereas patients with a body mass 
index < 25 kg/m2 had MVI at a rate of 1 4%. 
Question 4. Is MVI Related to the LT Outcome? 
The relationship between MVI and LT outcomes is still a matter of debate. The 
majority of studies favor the view of a relationship between MVI and poor 
posttransplant outcomes [1 -1 1 ,  35-53]. Many studies have reported a close 
correlation between the presence of MVI and a poor prognosis after LT; 
Bhattacharjya et al.[6] performed a prospective study of 30 patients treated with LT 
for relatively small HCCs (range = 6-75 mm). They found that the tumor size and the 
presence of multifocal tumors did not influence survival, but MVI, which was more 
common with larger tumors (38% with tumors < 4 cm and 60% with tumors > 4 cm, 
P < 0.01 ), influenced survival. Cescon et al.[25] reported a single-center series of 
283 patients who underwent transplantation for HCC between 1 997 and 2009; a 
Cox proportional hazards model showed that MVI was a predictor of lower 
recurrence-free survival (odds ratio = 4.82, 95% Cl = 1 .87-1 2.4 1 , P = 0.001 ). The 
fact that the Milan criteria did not appear to be prognostic may not be surprising 
because 89% of the patients fulfilled the up-to-7 criteria at the time of orthotopic LT. 
In a series of 51 patients undergoing LT for HCC, Choi et al .[37] retrospectively 
analyzed 5 cases of incidental HCC with a mean size of 1 .1 6 cm, no MVI, and good 
to moderate tumor differentiation. They found no recurrence of HCC in a mean 
follow-up period of 1 4  months. Lai et al.[47] reported that only MVI and exceeding 
the University of California San Francisco criteria were independent risk factors for 
recurrence in a multivariate analysis. However, many have reported that a 
combination of a larger tumor size, a higher histological grade (less differentiation), 
and MVI is the strongest factor related to recurrence and a poor prognosis after LT. 
Jonas et al.[5] found the presence of vascular invasion and the histological grade to 
be the only statistically significant independent predictors of poor survival after LT. 
In a study of 69 patients with HCC who underwent LT, Plessier et al.[54] reported 
that MVI was significantly correlated with the presence of satellite nodules (P < 
0.02) and a poor prognosis. 
On the other hand, a few studies have not been able to correlate poor results 
with MVI, although macrovascular invasion has been related to bad outcomes. Lee 
et al.[49] followed 38 patients after LT for HCC for a mean period of 1 7.7 months 
(range = 4-30 months), and they found that the number of tumor nodules and the 
presence of MVI did not affect tumor recurrence. Fan et al. [55] studied 1 078 
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patients who underwent orthotopic LT and found no correlation between MVI and 
overall or disease-free survival. Kornberg et al. [46] documented MVI as a risk factor 
for tumor recurrence after LT. A poor tumor grade (HR = 21.8, 95% Cl = 4.9-95.3, P 
< 0.001) and MVI (HR = 14.1, 95% Cl = 1.4-147.1, P = 0.027) were identified as 
independent risk factors for reduced recurrence-free survival after LT. 
Although the risk of recurrence is higher in patients with MVI, not all patients 
with MVI will experience recurrence. This has to be balanced with macrovascular 
invasion and satellite nodules (all detected by imaging techniques), which are 
contraindications for LT because of the high incidence of recurrence. 
Table 2 summarizes the publications documenting several types of tumor 
features, biomarkers, and imaging modalities. Table 3 summarizes the publications 
specifically documenting MVI and several of these issues, and available 
correlations are included. 
Table 2. Overview of Studies Several Tumor Characteristics 
Patient (n) Tumor Characteristics 
Meeting Radio I- Gross 
Milan ogical classifi-
Reference ana lyzed criteria size n �rade AFP DCP image cation 
Esnaola et al. [ 1 ]  245 245 + + + + 
Shah et al. [2] 1 54 1 54 + + + 
Parfitt et al. [3] 75 50* + + + + 
Lohe et al. [4] 97 47* + + + 
Jonas et al. [5] 1 20 1 20 + + + 
Bhattacharjya et al. [6] 30 30 + + + 
Shirabe et al. [7] 2 1 8  NM + + + + + 
Pawlik et al. [8] 1 073 NM + + + + 
Hui et al. [1 O] 65 65* + + + 
Sumie et al. [ 1 1 ]  1 1 0 1 1 0* + + + + + + 
Nakashima et al. [1 2] 209 209* + + + 
Kaibori et al. [1 3] 434 NM + + + + + 
Shirabe et al. [7] 1 1 9 65 + + + + + + 
Cucchetti et al. [ 1 6] 62 NM + + + + 
Kornberg et al. [1 8] 42 20* + + + + + 
Eg uchi et al. [21 ]  1 79 NM + + + + + 
Koike et al. [22] 227 NM + + + + 
Fujiki et al. [23] 1 44 79 + + + + + 
Cescon et al. [25] 283 208* + + + + 
Vibert et al. [26] 1 53 99 + + + + 
Ding et al. [31 ]  255 NM + + + + 
Tanaka et al. [32] 59 NM + + + + + + 
Cucchetti et al. [33] 250 1 90* + + + + 
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Siegel et al. [34] 
Roayaie et al. [35] 
Cucchetti et al. [36] 
Choi et al. [37] 
Dudek et al. [38] 
Plessier et al. [54] 
Mazzaferro et al. [39] 
Yao et al. [40] 
Coelho et al. [41 ] 
Park et al. [ 42] 
Vivarelli et al. [43] 
Silva et al. [44] 
Suh et al. [45] 
Kornberg et al. [ 46] 
Lai [47] 
D'Amico et al. [48] 
Lee et al. [49] 
Bargell i ni et al. [53] 










21 3  
1 39 
257 







*confirmed histopatho log ically 
NM + + 
NM + + + + 
NM + + + + 
NM + + + + 
48* + + + 
69 + + + 
444* + + + 
46* + + + + 
NM + + + + 
1 76* + + + + 
1 1 3* + + + + 
231 + + + + 
0 + + + + + 
27* + + + + 
59* + + + 
272* + + + + 
21 *  + + 
0 + + + + + 
394* + + + + 
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Table 3. Correlation between microvascular invasion and tumor characteristics 
Tumor characteristics 
Reference size (cm) number grade AFP DCP Radiological Gross 
Image classification 
Esnaola et al. [ 1 ]  + >4 + + poor/undiff NS 
Shah et al .  [2] + >3.6 + >3.8 NS 
Parfit et al .  [3] + >5 
Lohe et al .  [4] + >5 NS + intermediate/ high grade 
Jonas et al .  [5] + >5 + + Grade 2/3 
Bhattacharjya et al. [6] + >4 NS + mode/poor 
Shirabe et al. [7] + NS + NS + 
Pawlik et al. [8] 
+ 
+ high grade 
+ >=1 000 + 
multiple ng/ml 
Hui et al. [1 0] + CM 
Sumie et al .  [1 1 ]  + NS + NS NS + CM, IM 
Nakashima et al. [ 1 2] + SNEG, CM 
Kaibori et al. [ 1 3] + >5** NS + poor NS + >=200mAU/ml CD 
Shirabe et al. [ 14] + CM 
Kornberg et al .  [1 8] NS NS + poor NS + PET positive 
Eguchi et al. [21 ]  + >5 + + + + SNEG, CM, Inf 
Fujiki et al .  [23] NS NS + >=800 + >=400mAU/ml ng/ml 
+ rapid 
Vibert et al. [26] + >3 NS progre-
ssion*** 
Cucchetti et al. [33] + + + 
Siegel et al .  [34] NS + 
Silva et al .  [44] NS NS + poor + 
+ (bold); i ndependent predictor in multivariable analysis, + (not bold) ;  There was the correlation between mVI and the factor, but it was not an 
independent predictor, 
� 
NS: not sign ificant (there was no correlation . ) ;  (blank): Authours d idn't mention .  
* *  preoperative tumor size, *** 1 5µ/Umonth 
Abbreviations: poor, poorly d ifferentiated type; undiff, undifferentiated type; mode, moderately d ifferentiated type; CM, contiguous mu ltinodular type; IM, 
intrahepatic metastasis; SNEG, simple nodular type with extranodular g rowth type; Inf, infiltrative type. I\)
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Other issues that should be taken into consideration are as follows: 
1. The indication for LT in patients with HCC beyond the Milan criteria. Long-term 
survival is indeed achievable when MVI is absent; this emphasizes the need to 
find MVI biomarkers so that LT can be successfully performed for patients with 
HCC beyond the Milan criteria [50]. The use of the up-to-7 criteria [39] seems, 
however, to be a reasonable approach [51]. 
2. The pre-LT treatment. Because of the long waiting time before LT, more patients 
are being treated preoperatively (locoregional therapy). Furthermore, patients 
with tumors exceeding the Milan criteria are also being treated so that their HCC 
can be down-staged [52]. Locoregional tumor therapy has induced >50% tumor 
necrosis in two-thirds of cases. Even after down-staging, the overall survival and 
disease-free survival rates are lower than those for patients within the Milan 
criteria. However, in patients with HCC exceeding the Milan criteria, a complete 
response after transarterial chemoembolization (according to the amended 
Response Evaluation Criteria in Solid Tumors guidelines) has been associated 
with excellent posttransplant outcomes. The complete response was associated 
with lack of MVI in the expanded liver [53]. 
CONCLUSIONS 
1. MVI is an independent risk factor and/or one of the risk factors for HCC 
recurrence and poor outcomes after LT. However, a favorable prognosis can be 
expected when LT is performed for patients with small and well-differentiated 
HCC because MVI and HCC recurrence are rare in these cases. 
2. MVI is most l ikely to be present in tumors larger than 3 cm, in tumors whose 
gross pattern is the nodular type with extranodular growth or the confluent 
multinodular type, and in tumors with a high histological grade (which shows a 
less differentiated pattern). 
3. It is impossible to detect MVI preoperatively by conventional imaging modalities, 
and there is no widely recognized biomarker for predicting MVI. Because of the 
significance of MVI with respect to the recurrence of tumors and the prognosis, 
the possibility of predicting its presence by a comprehensive consideration of 
tumor characteristics (the size, histological grade, and number) and the potential 
role of imaging modalities should be further explored; before then, it should be 
better defined and graded. Further evaluations of the emerging roles of 
radiological, biological, and molecular profiling of HCC with an MVI signature are 
needed. Although the use of DCP is not popular in Western countries, its close 
relationship with the biological behavior of HCC suggests its potential as a 
biomarker of MVI, and it merits further study. 
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4. An artificial neural network may become useful for identifying the tumor grade 
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Background and aims: Recent studies showed that microvascular invasion 
(micro-VI), a frequent phenomenon in hepatocellular carcinoma (HCC), is a strong 
predictor for tumor recurrence and poor prognosis. 
Methods : To potentially establish a profile of micro-VI positive HCC we studied 
micro-VI in HCC of 43 transplanted patients, from the perspective of a three-step 
process of vascular invasion: tumor characteristics, epithelial-mesenchymal 
transition (EMT) and angiogenesis. Gene and protein expression of factors 
relevant to these 3 processes were investigated: cytokeratin 1 9  (CK19) and 
Epithelial cell adhesion molecule (EpCAM) as progenitor cell markers; EMT­
associated markers E-cadherin, Twist, Snail, S1 00A4, Matrix metalloproteinase-9, 
and angiogenesis markers consisting of Hypoxia inducible factor 1-a, vascular 
endothelial growth factor (VEGF)-A, Placental growth factor (PIGF), VEGF receptor 
(VEGFR)-1 , VEGFR-2, Angiopoietin (Ang)-1 ,  Ang-2, and Tie-2. 
Results : Our results showed that higher tumor grade, decreased tumor E-cadherin 
expression and a higher expression of PIGFNEGFR-1 in the adjacent non­
cancerous tissue were associated with micro-VI. Progenitor cell characteristics in 
the tumor were found in a relatively low frequency and there was no correlation 
with micro-VI. 
Conclusions : Our findings show that micro-VI in HCC are influenced not only by 
tumor characteristics but also by changes in the adjacent non-cancerous tissue. 
The higher tumor grade represents more aggressive tumor cells and the more 
prominent loss of E-cadherin is compatible with higher EMT activity. As 
PIGFNEGFR-1 is known to induce pathologic angiogenesis in which abnormal 
vessels are formed, higher PIGFNEGFR-1 expression in the adjacent tissue may 
potentiate vascular invasion . Grading of HCC can contribute to predicting micro-VI 
and the PIGFNEGFR-1 expression may provide a possible target of anti­
angiogenic treatment to inhibit the generation of abnormal vessels or to normalize 




Several recent studies have established the pivotal role of microvascular invasion 
(micro-VI) in hepatocellular carcinoma (HCC) as predictor for poor prognosis and 
tumor recurrence even after curative resection or liver transplantation [1, 2, 3, 4]. In 
the so far largest study of 1556 transplanted HCCs from 36 centers it was shown 
that the presence of micro-VI reduced the 5-year overall survival from 71.2% to 
47.4% in the group of patients who fell within the "up-to-7" criteria (HCC with 7 as 
the sum of the size of the largest tumor in cm and the number of tumor nodules) [3]. 
In this same group, tumor recurrence at 5 years is 9.1 % in the absence of micro-VI 
but increased to 39.9% when micro-VI is present. The major drawback of 
establishing micro-VI prior to surgery is the lack of widely recognized and reliable 
biomarkers [5]. To date, the most reliable identification of micro-VI in HCC can only 
be performed by histologic examination at the postoperative stage which forms a 
major obstacle to predict tumor behavior preoperatively and subsequent tailoring of 
therapy. Apart from the absence of markers for micro-VI, the molecular background 
of micro-VI in HCC is also poorly understood. 
Vascular invasion is a complex process which includes several steps : tumor 
cell proliferation on the primary site, epithelial-mesenchymal transition (EMT), 
extracellular matrix (ECM) degradation, cell migration/invasion and tumor 
angiogenesis [6, 7]. In this study we attempted to establish the cellular and 
molecular profile of micro-VI positive HCC by investigating vascular invasion from a 
3-step perspective: tumor potential, EMT and ECM degradation and angiogenic 
activity. Tumor characteristics that are known to be associated with micro-VI were 
documented [1, 8, 9], including size, number of tumor nodules, histologic grade 
and progenitor cell features. The latter have been reported to be associated with 
more aggressive tumor behavior and poor prognosis [10, 11]. E-cadherin, Twist, 
Snail, S1 00A4 and Matrix metalloproteinase-9 (MMP-9) were included as factors 
involved in EMT and ECM degradation. Hypoxia inducible factor 1 a (HIF-1 a) was 
included because this transcription factor has been reported to induce 
angiogenesis controlling genes in hypoxic condition and is also engaged in EMT 
via direct regulation of Twist [12]. Angiogenesis was studied by histologic 
evaluation of microvessel density (MVD) and gene-expression of the vascular 
endothelial growth factor (VEGF) family and the Angiopoietin (Ang) system as the 2 
best documented angiogenic systems. 
Our results demonstrate that micro-VI is associated with tumor characteristics 
(high-grade tumor), EMT (loss of E-cadherin) and an altered angiogenesis in the 
peritumoral tissue as indicated by the increased expression of placental growth 
factor (PIGF) and VEGF receptor (VEGFR)-1. 
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Patients and methods 
Patients and tissue samples 
Samples of HCC present in hepatectomy specimens of 43 patients who underwent 
liver transplantation for end-stage liver disease were included in this study. There 
were 34 male and 9 female patients with a median age of 56 years (interquartile 
range; 50-61 years). Gross and microscopic evaluation included tumor size, 
number of tumors, classification as within or beyond the Milan criteria, and 
histological grade according to Edmondson and Steiner classification. Micro-VI was 
defined histopathologically as the presence of cancer cell clusters within a vessel, 
using hematoxylin-eosin (H&E) staining and CD34 immunostaining. 
Gene expression analysis by real time reverse transcription polymerase chain 
reaction (quantitative RT-PCR) 
Fresh-frozen samples of 35 HCC and 25 adjacent non-cancerous tissue samples 
were available and subjected to RT-PCR assay to quantify the expression levels of 
messenger RNA (mRNA). An H&E stained slide of all samples was included to 
check the adequacy of the frozen samples. Total RNA was isolated using RNeasy 
Plus Mini Kit (Qiagen, Westburg, Leusden, The Netherlands) according to the 
manufacturer's instructions. The extracted RNA was analyzed qualitatively by 
agarose gel electrophoresis and quantitatively by Nanodrop ND -1000 
spectrophotometer (NanoDrop Technologies, Rockland, DE). The samples of total 
RNA were reverse transcribed with Random Hexamers (Promega, Leiden, The 
Netherlands) and Superscript Ill (lnvitrogen, Breda, The Netherlands) according to 
the manufacturer's instructions. Quantitative PCR was performed in an ABI PRISM 
7900HT Sequence Detector (Applied Biosystems, Foster City, CA) using TaqMan 
PCR assay probe/primers (Assay-on-Demand, Gene Expression Products, Applied 
Biosystems) for house keeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAP DH) (Hs99999905_m1 ), cytokeratin 19 (CK19) (Hs00761767 _s1 ), EpCAM 
(Hs00158980_m1), E-cadherin (Hs00170423_m1), Twist (Hs00361186_m1), Snail 
(Hs00195591_m 1 ), S100A4 (Hs00243202), MMP-9 (Hs00234579_m1 ), HIF-1 a 
(Hs00936366_m1), VEGF-A (Hs00173626_m1), PIGF (Hs00182176_m1), VEGFR-
1 (Hs01052936_m1), VEGFR-2 (Hs00176676), Ang-1 (Hs00181613_m1), Ang-2 
(Hs00169867_m1), and Tie-2 (Hs00176096_m1). 10 ng complementary DNA was 
applied for each PCR reaction and all PCR reactions were performed in triplicates. 
Average cycle threshold (Ct) values per triplicate were calculated for each gene of 
interest and house keeping gene, yielding �Cts. To determine the gene 
expression levels of gene of interest relative to the house keeping gene we next 
calculated the 2-t1ct values. Control samples of distilled water and RNA isolates that 




All primary antibodies used in this study and their dilutions are listed in Table 1. 
Four-micrometer thick samples were cut from formalin-fixed, paraffin-embedded 
liver samples which contained both HCC and adjacent non-tumorous tissue. 
lmmunostaining for E-cadherin, CK19, EpCAM and CD34 was performed on the 
DAKO autostainer (DAKO, Glostrup, Denmark). For Twist, Snail, and S100A4 
staining, sections were incubated with the primary antibody (Twist, Snail, S1 00A4) 
for one hour at room temperature and stained with the DAKO EnVision + System­
HRP Kit (K4009, DAKO) according to the manufacturer's instructions after antigen 
retrieval. As chromogen 3-amino-9-ethylcarbazole chromogen (DAKO) was applied 
and hematoxylin (Merck, Darmstadt, Germany) was used as the nuclear 
counterstain. For VEGF, PIGF and VEGFR-1 staining, frozen sections of 4 µm 
were incubated overnight at 4°C with the primary antibodies after drying, acetone 
fixation and blocking of endogenous peroxidase by 30 minutes incubation with 
0.3% H202 at room temperature. The subsequent steps were similar to those 
described above. 
Table 1 .  Primary a ntibodies used in immunohistochemistry 
Antibody Dilution Company Catalog No. 
BD Transduction 
Mouse monoclonal a nti-E-cadherin [36] 1 :4000 Laboratories C20820 
Mouse monoclona l a nti-CK1 9 [RCK1 08] 1 : 1 00 DakoCytomation M0888 
Mouse monoclonal anti-EpCAM [Ber-EP4] 1 : 1 00 DakoCytomatio n M0804 
Mouse monoclonal a nti-CD34 [QBEnd-1 0] 1 :20 DakoCytomation M71 65 
Rabbit polyclonal a nti-Twist 1 :300 Abeam ab50581 
Rabbit polyclonal anti-Snail+Slug 1 :500 Abeam ab85931 
Rabbit polyclonal a nti-S1 00A4 1 :200 DakoCytomatio n A51 1 4  
Rabbit polyclonal anti-VEGF-A (A-20) 1 : 1 00 Santa Cruz sc- 152 
Rabbit polyclonal a nti-PIGF 1 : 1 00 Abeam ab9542 
Rabbit polyclonal anti-VEGFR-1 1 : 1 00 Abeam ab2350 
All primary antibodies were diluted in 1 % bovine serum albumin/phosphate- buffered saline. 
Evaluation of immunoreactivity 
Semiquantitative assessment of E-cadherin expression was performed according 
to the method of Asayama et al. in which staining is graded as: 'preserved' if more, 
and 'reduced' if less than 90% of tumor cells showed a membranous expression 
[13]. For CK19 and EpCAM, if more than 5 % of tumor cells showed membranous 
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expression it was considered positive [11 ]. For Twist and S1 00A4, the staining was 
considered positive if more than 10% and 30% of tumor cells respectively showed 
nuclear expression [14, 15]. The evaluation was performed by two liver 
pathologists (ASHG and HK) blinded to the patients' clinicopathological data. 
Determination of MVD 
MVD was assessed in HCC tissues of which paraffin embedded sections were 
stained with anti-CD34 antibody and scanned on NanoZoomer 2.0-HT 
(Hamamatsu Photonics, Japan). The observation and the area measurement were 
done using NOP viewer software (Hamamatsu Photonics). First, five areas of 
0.74mm2 with the most intense staining (hot spots) were selected. Regardless of 
the vessel lumen structure, every stained cell in the hot spot was counted as one 
microvessel. In the case that a positive staining appears to be linear and to outline 
nests of tumor cells, we used a modified counting method introduced by Tanigawa 
et al, in which the length of a microvessel of 40 micrometer was calculated as one 
point [16]. The average of 5 areas counts expressed as the absolute number of 
microvessels per 0. 7 4mm2 was taken as the MVD. 
Statistical analysis 
Quantitative data were expressed as median and interquartile range. A two-tailed 
nonparametric test was used for comparison of groups; either the Mann-Whitney U 
test for non-related samples (comparison between micro-VI negative and positive 
group) or the Wilcoxon signed-ranks test for related samples (comparison between 
HCC and adjacent non-tumorous tissue). Categorical variables were compared 
using Fisher's exact test. P values of less than 0.05 were considered statistically 
significant. All statistical analysis was performed using PASW Statistics 18 
software (SPSS, Chicago, IL, USA). 
Results 
Tumor characteristics : higher tumor grade is associated with micro-VI 
From a total of 43 cases, 30 cases (70%) showed micro-VI. The median of the 
largest tumor size and the number of tumors were 2.6 cm (interquartile range: 2-4.1 
cm) and 2 (interquartile range: 1-5) respectively. There was a significant difference 
in tumor grade between the micro-VI positive and micro-VI negative groups 
(P=0.039). Nine cases were high grade tumors (Edmondson Ill-IV), and all these 
cases showed micro-VI. Among 34 low grade cases (Edmondson I- 11), 21 cases 
(62%) showed micro-VI. Comparisons of patient and tumor characteristics 
according to the presence/absence of micro-VI are shown in Table 2. There was no 
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statistical difference between the absence and presence of micro-VI based on age, 
gender, tumor size, number of tumor nodules, postoperative status of Milan criteria, 
and microvessel density. In our series, 2/43 HCCs contained CK19-positive cells 
(4.6%) and 6/43 EpCAM-positive cells (18%). In the micro-VI negative group 
(13/43) there were 2 EpCAM-positive cases and no CK19-positive case, whereas 
in the micro-VI positive group (30/43) there were 4 EpCAM-positive cases and 2 
CK19-positive cases. No correlation was found between micro-VI and the cases 
expressing these progenitor markers. 
Table 2. Patient and tumor characteristics 
micro-VI negative micro-VI positive P value 
n = 1 3  n= 30 
Age, median (range) 59 ( 48-66 yrs) 54 (50-60 yrs) 0 .222 
Male/female 1 1 /2 23/7 0 .699 
HCV negative / positive 1 0/3 22/8 
HBV negativ / positive 1 3/0 28/2 
Tumor size <5cm I >5cm 1 2/1 20/1 0 0 . 1 29 
Number of tumors; single / multiple 4/9 1 3/1 7 0.51 3 
Milan criteria; within / beyond 8/5 1 6/ 14  0 .743 
Edmondson  grade; I and I I / I l l  and IV 1 3/0 2 1 /9 0 .039 
CK1 9 negative / positive 1 3/0 28/2 
EpCAM negative / positive 1 1 /2 26/4 
CD34-MVD 31 1 ± 74 290 ± 99 
0 .472 
Gene and protein expression studies 
The results of the quantitative RT-PCR analysis are summarized in Fig. 1 and 2. 
Fig. 1 demonstrates the comparison of gene expression levels between the micro­
VI negative and positive group, and Fig. 2 demonstrates the comparison of gene 
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Figure 1 .  Comparison of gene expression levels between microvascular invasion (micro-VI) 
negative and positive group in HCC tissue (negative; n=1 1 ,  positive; n=24) or adjacent 
noncancerous tissue (negative; n=8, positive; n=1 7). 
Box-plot graphs showing relative gene expression for CK1 9 (A) , EpCAM (B), E-cadherin (C) , Twist (D), 
Snail (E) ,  S1 00A4 (F), MMP-9(G) , HI F- 1A  (H), VEGF (I) , PIGF (J), VEGFR-1 (K), VEGFR-2 (L) ,  Ang-1 
(M) ,  Ang-2 (N) ,  Tie-2(O). The box a nd the horizontal l ine ins ide the box represent the interquartile (25-
75%) range and the med ian value respective ly. Capped bars ind icate the 5th and 95th percentiles a nd 
smal l  dots the outliers. *P<0.001 , **P<0.05 
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Figure 2. Comparison of gene express ion levels between HCC and adjacent noncancerous tissue 
in microvascular invasion (micro-VI) negative group (8 paired) or micro-VI positive group ( 17  
paired). 
Box-plot graphs showing relative gene expression for CK1 9 (A), EpCAM (B), E-cadherin (C) , Twist (D), 
Snail (E), S1 00A4 (F) ,  MMP-9(G) , HIF- 1A (H) ,  VEGF ( I ) ,  PIGF (J) , VEGFR-1 (K), VEGFR-2 (L) ,  Ang-1 
(M), Ang-2 ( N) ,  Tie-2(O). The box a nd the horizontal l i ne inside t he box represent the interq uartile (25-
75%) range a nd the med ian value respectively. Capped bars i nd icate the 5th and 95th percentiles a nd 
small dots the outliers. *P<0.05, **P<0.01 , ***P<0.001 
Progenitor cell characteristics: no differences between micro-VI positive and 
negative groups 
Since the CK19 mRNA was not amplified in most HCC tissues in the qRT-PCR 
study, we excluded it from Fig. 1 (A) and 2(A). In contrast EpCAM mRNA was 
properly amplified in both HCC and adjacent tissue. Micro-VI negative and positive 
tumors as well as the adjacent tissue of both groups did not show significant 
differences regarding EpCAM expression (Fig. 1 (8) and 2(8)). However, there was 
a significantly lower gene expression level of EpCAM in the tumor compared with 
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its adjacent tissue in both the micro-VI negative and positive groups, and this 
difference was more prominent in the micro-VI positive group. 
Figure 3. lmmunoh istochemistry for EpCAM, E-cadherin and Twist in adjacent non-tumorous 
tissue (left panel) and HCC (right panel). 
EpCAM: Left panel: some non-tumorous hepatocytes at the periphery of a cirrhotic nod ule are positive 
for EpCAM (arrows), as are all bile ductules (arrow heads) . Right panel: example of an EpCAM positive 
HCC and EpCAM negative hepatocytes in the neig hbouring cirrhotic nodule (CN) Bile d uctules 
surrounding the cirrhotic nod u le are EpCAM positive (arrow heads) 
E-cadherin: left panel: non-tumorous hepatocytes and s urround ing d uctules (arrow heads) are positive 
for E-cadherin. Right panel: loss of E-cadherin expression on tumor cells. 
Twist: left panel: nuclear and cytoplasmic expressio n  of Twist in d uctules (arrow heads) s urrounding 
cirrhotic nodule (CN) in which the hepatocytes show cytoplasmic but no nuclear Twist expression. Right 
panel: diffuse nuclear and cytoplasmic expression of Twist in HCC. 
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lmmunohistological distribution of CK19 and EpCAM expressing HCC was 
mentioned above as part of the tumor characteristics. In the adjacent tissue, CK19 
and EpCAM were predominantly expressed by cholangiocytes of biliary ductules. 
These ductules were readily found in areas adjacent to non-cancerous cirrhotic 
nodules but were scarce or absent at the margins of HCC nodules (Fig. 3). Some 
cases also showed small rims of EpCAM positive hepatocytes in the non­
cancerous cirrhotic nodules while there were no cases showing CK19 positive 
hepatocytes. 
EMT related factors: decreased E-cadherin in micro-VI positive HCC Micro-VI 
positive HCC showed lower E-cadherin mRNA expression than micro-VI negative 
HCC (P<0.001) but between HCC and their adjacent non-cancerous counterparts 
there was no significant difference. The adjacent non-cancerous tissue of the 
micro-VI positive and negative groups did not show differences in E-cadherin levels 
either. The gene expression level of Twist was significantly lower in HCC compared 
to its adjacent tissue in the micro-VI positive group. Compared to the adjacent non­
cancerous tissue Snail expression in HCC was significantly lower both in the micro­
VI positive and micro-VI negative groups. Comparisons between micro-VI negative 
and microVl-positive groups revealed no significant differences in the gene 
expression levels of Twist, Snail, and S1 00A4. 
The results of the immunohistochemistry are summarized in Table 3. In the 
micro-VI negative group, 2/13 cases showed reduced E-cadherin expression, 
whereas in the micro-VI positive group, 15/30 cases showed this decrease 
including complete loss of E-cadherin in one case. The reduced protein expression 
of E-cadherin was correlated with micro-VI (P=0.045). In the neighboring non­
cancerous tissue E-cadherin expression was present on hepatocytes and ductular 
cells (Fig. 3). lmmunohistologically, most tumor cells showed cytoplasmic 
expression of Twist, and 10 cases showed positive nuclear expression of Twist 
including one case with diffuse nuclear expression. In addition, we observed 
ductular cells around cirrhotic nodules in adjacent non-cancerous tissue that also 
showed nuclear expression of Twist (Fig. 3). None of the cases showed expression 
of S1 00A4 in tumor cells while the vascular wall of the unpaired arteries in HCC 
and stromal cells, inflammatory cells and Kupffer cells were positive for S100A4. 
Of note, ductular cells in the adjacent non-cancerous tissue also showed positive 
cytoplasmic expression for S1 00A4. 
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Table 3. Comparison of the results of immuno histochemistry for EMT markers dependent on the 
existence of micro-VI 
E-cadherin preserved/reduced or absent on tumor hepatocytes 
Twist negative/positive on tumorhepatocytes 
Twist negative/positive on d uctules in NT part 
Snail negative/positive on tumor hepatocytes 
Snail negative/positive on d uctules in NT part 




1 1 /2 
1 0/3 
7/6 
1 1 /2 
1 1 /2 
1 3/0 
micro-VI 
positive P value 
1 5/1 5 0 .045 
21 /9 0.727 
1 1 /1 9 0 .332 
28/2 0 .572 
25/5 
30/0 
Angiogenesis : the adjacent tissue of the micro-VI positive group showed 
increased expression of PIGFNEGFR-1 
Apart from PIGF, mRNA expression levels of all studied angiogenesis related 
factors showed no differences between the micro-VI positive and micro-VI negative 
groups. The expression level of PIGF mRNA in the adjacent tissue of the micro-VI 
positive group was significantly higher compared to that of the adjacent tissue of 
the micro-VI negative group (P=0.021) (Fig. 1 (J )). A similar trend was found for 
VEGFR-1 although the difference was of statistical borderline significance (P= 
0.057) (Fig. 1 (K)). When we compared HCC with its adjacent tissue, the 
expression of PIGF, VEGFR-1, and Tie-2 were significantly higher in the adjacent 
tissue in the micro-VI positive group (Fig. 2(J), (K), and (0)) which was not the 
case in the micro-VI negative group. 
lmmunohistologically VEGF, PIGF, and VEGFR-1 were present on vascular 
and sinusoidal endothelial cells in HCC and non-cancerous adjacent tissue in both 





Figure 4. lmmunoh istochemistry for VEGF, PIGF, and VEGFR-1 in HCC and adjacent tissue. 
lmmunohistochemistry showing expression of VEGF, PIGF and VEGFR-1 in t umor endothe lia l cells 
(short arrows) and vascular and sinuso idal endothelial cells (arrowheads and long arrows) in the 




In this study, we investigated the profile of micro-VI in HCC from a 3 levels­
perspective: tumor potential, EMT related factors, and angiogenic potential. Our 
results showed that micro-VI positive HCC is characterized by a high-grade tumor 
and decreased E-cadherin expression by tumor cells while the adjacent non­
cancerous compartment contains an increased expression of the angiogenic 
factors PIGF and VEGFR-1. 
Of the several tumor characteristics that were assessed, a higher tumor grade was 
the only feature that significantly distinguished the micro-VI positive HCC from the 
micro-VI negative one. A number of other studies reported variable correlations 
between micro-VI with tumor size, tumor grade and number of tumor nodules [5]. 
These inconsistencies may be influenced by the fact that HCC nodules within a 
cirrhotic liver represent both multifocal malignant transformation of cirrhotic nodules 
and intra organ metastases. These 2 types of nodules which are distinguishable by 
molecular analysis only and not by routine histology, represent different modes of 
tumor growth, i.e., oligoclonal expansion and metastatic growth [19, 20]. Intra 
organ metastatic nodules have been reported to be associated with more 
aggressive growth compared to multicentric tumor nodules, leading to portal-vein 
invasion,  higher incidence of tumor recurrence and poor suNival [20]. Furthermore, 
differences in sample size of the studies, variable definitions of micro-VI and 
protocols of histopathological tumor examination may also contribute to the 
inconsistent correlations. Nevertheless, a correlation of micro-VI and high-grade 
HCC within size-and-number group categories has been established in the 
Metroticket study which so far represents the largest cohort of HCC ever published, 
comprising 1556 patients from 36 centers [3]. High grade tumors are less 
differentiated tumors with more aggressive behavior, i.e. , exhibiting more invasive 
potential. 
Tumor aggressiveness is amplified by the presence of cancer cells with stem 
cells signatures (CSS), a phenomenon that has also been obseNed in HCC in 
which CSS is defined by the expression of e.g., CK19, EpCAM, CD133 [10, 21, 22]. 
A recent  study reported an association between macrovascular invasion and 
hematogenous metastasis in the presence of a subpopulation of CSS defined as 
CD133+/CD44high tumor cells in HCC [23]. Another study showed a correlation of 
both macro-VI and micro-VI with HCC containing CK19 positive cells in which 18% 
of the cases contained CK19 positive CSS [1 O]. Both on the gene and protein 
expression levels of CK19 and EpCAM, we found a lower frequency of CSS 
containing tumors than others and no correlation between CSS containing HCC 
with micro-VI. A difference in etiology of the underlying liver diseases may 
influence these discrepancies. Both hepatitis B virus (HBV) and hepatitis C virus 
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(HCV) have been reported to induce CSS in HCC [24, 25] but only 30% of our 
cases were HCV or HBV related in contrast with 85% of the cases in the series of 
Kim et al [10]. 
In the micro-VI positive group we found a decrease of gene and protein 
expression of E-cadherin by HCC cells which is regarded as a man ifestation of 
EMT and an important initial step in the tumor invasion process due to the loss of 
cell-cell adherence [26]. The other studied EMT related factors did not distinguish 
between micro-VI positive and negative groups. The low expression of Snail and 
Twist in the tumor matches the low expression of CSS features in our HCC as 
expression of these EMT transcription factors is associated with CSS properties 
[10, 27]. Accordingly, nuclear protein expression of Snail and Twist in tumor cells 
was also found in a few cases only. 
The potential importance of changes in peritumoral tissue in the 
pathogenesis of micro-VI is illustrated by the finding of a higher expression of PIGF 
and VEGFR-1 in the non-cancerous adjacent tissue of micro-VI positive HCC 
compared to the expression levels in the tumor. Results of several studies in tumor 
models have established the central role of the PIGFNEGFR-1 signaling in tumor 
angiogenesis. PIGF stimulates endothelial cell growth, survival and migration in 
pathological conditions but appears to be redundant in normal vascular 
development and maintenance [28, 29]. Under pathological conditions PIGF 
potentiates the angiogenic response to VEGF by displacement of VEGF from 
VEGFR-1 to VEGFR-2 and by activating VEGFR-1. The synergy of VEGF 
mediated VEGFR-2 activation and PIGF mediated VEGFR-1 activation leads to 
amplification of the angiogenic response [28]. Overexpression of PIGF stimulates 
tumor growth due to increased tumor vascularization consisting of abnormal blood 
vessels with incomplete coverage by pericytes and an irregular basement 
membrane [30]. Conversely, blockage of PIGF inhibits tumor vessel arterialization 
and abnormalization and also impedes tumor growth in experimental HCC without 
significant effect in vessel density [31]. Based on these tumor-angiogenic 
characteristics it is conceivable that the increased PIGFNEGFR-1 expression in 
the adjacent tissue could stimulate generation of abnormal vessels that are 
permissive to invasion due to its abnormal architecture. Whether such a process 
truly exists in micro-VI positive HCC and may be inhibited by anti-PIGF would need 
further investigation. 
In summary, we found that the profile of micro-VI positive HCC consists of 
high grade HCC and loss of tumor E-cadherin while the adjacent non-cancerous 
tissue showed increased expression of PIGF and VEGFR-1. The grading of HCC 
might contribute in predicting the presence of micro-VI along with other diagnostic 
tools, e.g., imaging studies. The PIGFNEGFR-1 activity may provide a target to 
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anti-angiogenic therapy to inhibit abnormal vessel formation and decrease 
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Microvascular invasion (micro-VI) is a frequent finding and strong prognostic 
marker in patients with hepatocellular carcinoma (HCC) for which there is no 
reliable predictive marker before surgery. Due to its microscopic nature the 
diagnosis is based on histopathological examination of the resected tumor. In a 
previous study we found evidence that micro-VI is associated with alterations in the 
angiogenic status of the peritumoral area. To further investigate the association 
between micro-VI and peritumoral changes we focused on the peritumoral area 
and investigated the changes herein in comparison with stromal areas distant from 
the tumor. 
We isolated the peritumoral fibrous septa (PT septa) and fibrous septa 
distant to the tumor (D septa) using laser microdissection technique in 11 HCC 
livers and measured the gene expression levels of factors possibly related with 
micro-VI. Those were growth factors related with angiogenesis, epithelial 
mesenchymal transition and factors characterizing hepatic progenitor cells. 
We found decreased gene expression levels of epithelial cell adhesion 
molecule (EpCAM) and E-cadherin within PT septa relative to its corresponding D 
septa in the micro-VI positive HCCs, not in micro-VI negative HCCs. A parallel 
finding on the protein level was manifested by decreased numbers of EpCAM 
positive ductules in the PT septa. The association of micro-VI with significantly 
lower numbers of ductules in the PT septa compared with its D-septa was 
confirmed by a validation study in a second cohort of 25 patients. 
Conclusion: Our findings confirm that several types of changes in 
peritumoral areas may play a role in micro-VI in HCC which corroborate the notion 
that the tumor microenvironment can contribute to cancer growth and progression. 
From a diagnostic practical perspective our finding may also be a potential 




It is well known that macrovascular invasion in hepatocellular carcinoma ( HCC), 
which can be diagnosed before surgery by conventional imaging modalities, is a 
poor prognostic factor and a contraindication to surgical treatments [1 ]. 
Microvascular invasion (micro-VI), which is a frequent phenomenon in HCC is also 
an independent prognostic factor [2, 3] associated with tumor recurrence and poor 
survival [4]. In contrast with macrovascular invasion, the presence of micro-VI can 
only be identified by histopathological examination of the resected specimen due to 
its microscopic nature and the lack of reliable predictive markers before surgery [5]. 
Recently Kim et al showed that peritumoral hypointensity seen on the hepatobiliary 
phase of gadoxetate disodium-enhanced magnetic resonance imaging is a highly 
specific radiological marker predictive of micro-VI although with insufficient 
sensitivity of 38.3% [6]. Paraoxonase 1A, identified by proteomic analysis, is 
recently reported as a promising serum biochemical predictor for micro-VI with 
moderate accuracy [7]. Although recent progress on imaging modalities and 
proteome analysis is uncovering relevant markers for micro-VI, to date there is still 
no reliable predictive marker with sufficiently high sensitivity and specificity. 
In a previous study we documented that a HCC containing micro-VI is 
characterized by high grade tumor, significant loss of E-cadherin by tumor cells and 
increased gene and protein expression of VEGFR1 and PIGF in the adjacent non­
cancerous tissue [8]. The latter finding of abnormal angiogenic status in the tumor 
surrounding tissue is compatible with recent insights that cancer stromal tissue is 
not a passive bystander, but is actively involved in cancer progression and invasion 
of cancer cells [9, 1 O]. 
To further investigate the changes in tumor stroma associated with micro-VI 
we designed the present study in which we focused on the fibrous septa adjacent 
to HCC, the peritumoral (PT) septum and fibrous septa surrounding cirrhotic 
nodules distant from the tumor (D) present in the same liver. The septa were 
isolated by laser microdissection (LMD) and we studied gene and protein 
expression of factors involved in angiogenesis and epithelial mesenchymal 
transition (EMT). Factors related to liver progenitor cell characteristics, epithelial 
cell adhesion molecule (EpCAM) and cytokeratin 19 (K19) were also included as 
the septa also contain biliary ductules which harbor these progenitor cells. 
Following the identification of the genes that distinguish micro-VI positive from 
micro-VI negative HCC, the expression of the related proteins were studied in a 
second cohort of 25 HCC samples to validate the initial findings. 
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Patients and Methods 
Patients and tissue samples 
Archival liver tissue samples were obtained from patients who underwent liver 
transplantation for cirrhosis associated HCC at the University Medical Center 
Groningen. The largest tumor diameter, number of tumor-nodules, histological 
grade (according to Edmondson and Steiner classification), and the presence of 
micro-VI were evaluated on the available paraffin sections. 
Eleven cases of which frozen tissue samples were available containing both 
PT septa and D-septa were included as the first cohort of the LMD study and 
subsequent gene expression analysis. 
The validation study consisted of a second cohort of 25 HCC samples 
subjected to immunohistochemical study. Two paraffin sections of each case were 
used in this study, one containing a PT-septum and another one of the 
corresponding cirrhotic liver, sampled at least 3 cm distant from the tumor, for the 
D-septum. 
Laser microdissection 
Fresh frozen tissues were taken from PT-stroma and a sample of the D-septum 
located at least 3cm distant from the tumor. Nine-µm cryosections mounted on 
polyethylene terephthalate membrane frame slides (Leica Microsystems, Wetzlar, 
Germany) were fixed in cold acetone for 2 minutes, stained with Mayer's 
hematoxylin for 1 minute, washed with diethyl pyrocarbonate-treated water, and 
air-dried. LMD was performed using a Leica LMD6500 microdissection system 
(Leica Microsystems). Tumor cells and hepatocytes were excluded carefully. 
Figure 1 shows representative pictures before and after LMD. The average surface 
area of the microdissected area in each case was 9 mm2 . 
Fig ure 1 .  Photomicrograph of a peritumoral septum before (A) and after (B) microdissection. 
T: tumor. C: cirrhotic nod ule. 
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Gene expression analysis by quantitative real-time reverse transcription 
polymerase chain reaction 
Total RNA was isolated from these microdissected samples by using RNeasy Plus 
Micro Kit (Qiagen , Westburg , Leusden , the Netherlands) according to the 
manufacturer's instructions . The samples of total RNA were reverse transcribed 
with Random Hexamers (Promega, Leiden, the Netherlands) and Superscript Ill 
(lnvitrogen , Breda , The Netherlands) according to the manufacturer 's instructions. 
RT- PCR was performed in an AB I  PRISM 7900 HT Sequence Detector (Applied 
Biosystems , Foster City , CA) using TaqMan PCR assay probe/primers (Assay-on­
Demand , Gene Expression Products , Applied Biosystems) for house keeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1 ), K19 
(Hs00761767_s1), EpCAM (Hs00158980_m1), E-cadherin (Hs00170423_m1), N­
cadherin (Hs00983056_m1), Snail (Hs00195591_m1), S100A4 (Hs00243202), 
MMP-2 (Hs01548727_m1), MMP-9 (Hs00234579_m1), H IF-1a (Hs00936366_m1), 
PIGF (Hs00182176_m1), VEGF-A (Hs00173626_m1), VEGFR-1 
(Hs01052936_m1), VEGFR-2 (Hs00176676), Ang-1 (Hs00181613_m1), Ang-2 
(Hs00169867 _m 1 ), Tie-2 (Hs00176096_m1 ), and CD34 (Hs00990732_m 1 ) .  
Duplicate real-time RT- PCR analyses were executed for each sample , and the 
threshold cycle values (Ct) were analyzed by using Sequence Detector Systems 
version 2.4 software (Applied Biosystems). Gene expression was normalized to the 
expression of the housekeeping gene GA P D H ,  and relative mRNA level was 
calculated by Tllct method . Control samples of d istilled water were consistently 
found to be negative . 
lmmunohistochemistry 
Four µm paraffin sections were deparaffinized in xylene and graded ethanol. After 
enzymatic digestion with 0.1 % proteinase (CAS Number 9014-01-1 , Sigma­
Aldrych , Zwijndrecht ,  the Netherlands) for 15 minutes and endogenous peroxidase 
blocking with 0.3 % H2O2 for 30 minutes , slides were incubated with anti-EpCAM 
mouse monoclonal antibody (dilution; 1: 1500 , clone VU-1 D9 , Cat. No . OP187-
100 UG , Merck Chemicals , Darmstadt , Germany) overnight at 4°c and stained with 
the DAKO EnVision + System-HR P (Cat. No. K4006, DAKO, Glostrup , Denmark) 
according to the manufacturer 's instructions . After the color development with 3 ,3 ' ­
Diaminobenzidine , hematoxylin was used as a nuclear counterstain. 
Evaluation of EpCAM staining 
A relative comparison of the number of EpCAM-positive ductules in fibrous septa 
was done between the PT and D-septa for each individual case. Representative 
septal areas of similar width were selected , photographed and compared with each 
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other on screen. The results were categorized into three groups with regard to the 
contents of EpCAM positive ductules: PT> D (PT area contains at least more than 
10% of ductules than the distant area) 10%); PT=D (the difference in number of 
ductules does not exceed 10%); and PT< D (PT septum contains at least 10% less 
ductules than the D septum). The evaluation was performed by two liver 
pathologists (ASHG and HK) blinded to the patients' clinicopathological data. 
Statistical analysis 
In the gene expression study, a two-tailed nonparametric test was used for 
comparison of groups; either the Mann-Whitney U test for non-related samples 
(comparison between micro-VI negative and positive group) or the Wilcoxon 
signed-ranks test for related samples (comparison between close and distant area). 
In the immunohistochemical study, categorical variables were compared using 
Fisher's exact test (2x3 crosstabs analysis). Two tailed P values of less than 0.05 
were considered statistically significant. All statistical analysis was performed using 




Gene expression analysis of the first cohort 
The results of the gene expression analysis were summarized in figures 2 and 3. 
When we compared PT with D-septa within each of the micro-VI groups, only in the 
micro-VI positive group there was a significant difference with regard to EpCAM 
and E-cadherin expression. PT septa showed a lower expression than D septa for 
both EpCAM (p= 0.03) and E-cadherin (p=0.02) (red rectangle in figure 2). All 
angiogenic and other EMT related factors did not show significant differences. 
Comparison between the micro-VI positive with the micro-VI negative groups did 
not show differences in gene expression levels for all tested factors, both in PT and 
D septa (Fig.3). 
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Figure 2. Comparison of ge ne expression levels between peritumoral septa (PT) and distant septa (D) 
in microvascular invasion negative group (PT- and D-) or microvascular invasion positive group (PT+ 
and D+) .  Boxes represent the interquartile (25-75%) range and the median values. Capped bars 
indicate the 5th and 95th percentiles a nd small dots the outliers. *= p<0.05. 
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Fig ure 3. Comparison of gene expression levels between microvascular invasion negative and positive 
groups i n  peritumoral septa (PT- and PT+} or septa distant to primary tumor (D- and D+). Boxes 
represent the interquartile (25-75%) range and the med ian value. Capped bars ind icate the 5th and 95th 
percentiles and small dots the outliers. 
lmmunohistochemistry in the first cohort 
EpCAM and E-cadherin staining were performed as these were the 2 proteins that 
showed a significant difference in gene expression level between the PT and D 
septa in the micro-VI positive HCC. Both proteins were diffusely expressed by 
biliary ductular cells which represent the only epithelial cell component in the PT 
and D septa along with ductal cells of a few bile ducts. No hepatocytes were 
present in the septa studied. To further evaluate the background of differences 
between the PT and D septa, the number of ductules in both septa was 







Figure 4. Representative pictures of EpCAM staining in fibrous septa. Two pictures next to each other 
(A and B, C and D, or E and F) were taken from the same liver. The relative comparison of the number 
of EpCAM positive ductules between the two septa was classified into PT<D, PT=D, and PT>D, 
respective ly. Blue lines ind icate the rim between tumor (T) or cirrhotic (C) nodule and fibrous septum. 
Arrowheads: EpCAM expressing ductules. Red arrowheads: ductules. 
Analysis of the number of ductules in PT and D septa showed similar numbers of 
ductules in 5 out of 11 cases (45%). In another 5 cases (45%), the PT septa 
showed lower numbers of ductules and all these 5 cases were micro-VI positive. 
One out of 11 micro-VI negative case showed more ductules in the PT septa (22%). 
Although these results were not statistically significant there was a similar trend 
with the gene expression levels of EpCAM. Further analysis to validate these initial 
findings was carried out in the second, larger cohort of 25 HCC samples. 
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lmmunohistochemistry of the second validation cohort 
Results were summarized in figure 5. As shown, the number of ductules in PT and 
D septa was similar in 10 out of 25 cases (40%). In 8 out of 25 cases (32%), the PT 
area showed lower numbers of ductules, and all these 8 cases were micro-VI 
positive HCC. On the other hand, the PT septa showed more ductules in 7 out of 
25 cases (28%), and 6 out of 7 were micro-VI negative HCC. In this larger, 
validation cohort, a significant relationship between micro-VI status and the number 
of ductules was identified (P=0.003). Lower numbers of ductules in PT area 
compared with D-septum is associated with the presence of micro-VI whereas a 










Figure 5. Distribution of the individual cases of the second cohort (n=25) in  the 3 categories of the 
comparison between the PT and D-septa regarding the number of EpCAM positive d uctules. 




As a follow up of our previous study in which we found that the distinction between 
micro-VI positive and negative HCC was not only determined by tumor cell 
characteristics but also by differences in the tumor stroma, we performed the 
present study in which we focused on the PT stroma and D-septa. These stromal 
areas were isolated by LMD for gene expression analysis. 
We found that PT septa of micro-VI positive and negative HCC did not show 
differences in gene expression of all tested angiogenic and EMT related factors as 
well as progenitor cell characteristics. A similar pattern was found for the D-septa. 
However, comparison of PT with D septa within the groups revealed a significant 
difference within the micro-VI positive group, but not in the micro-VI negative group, 
with regard to EpCAM and E-cadherin gene-expression. Both factors were 
significantly lower in the PT septa as compared with the expression in the D septa. 
As the protein expression of both factors could only be present in the ductular cells 
due to the absence of any other epithelial structures within the septa we concluded 
that differences in the number of ductules between the PT and D septa may 
underlie the pattern of the EpCAM and E-cadherin gene expression. EpCAM 
positive ductules in paraffin sections of PT and D septa were comparatively 
evaluated and a trend was observed toward an association between lower number 
of ductules in the PT septum and micro-VI positive HCC. To further validate the 
observed trend in the first cohort a similar comparative evaluation of EpCAM 
positive ductules were performed in a second and larger cohort of 25 HCC samples. 
In this validation cohort it was found that lower number of ductules in PT 
septum relative to the corresponding D septum is significantly associated with the 
presence of micro-VI. Conversely, higher number of ductules in the PT septum 
compared to the D septum is associated with absence of micro-VI. 
Our results are in line with the findings by Lennerz et al who investigated the 
ductules in HCC from the perspective of hepatocarcinogenesis [11]. They 
documented that loss of perinodular K19 positive ductules parallels the stepwise 
malignant transformation of cirrhotic nodules to high grade dysplasia and HCC and 
showed that the ductular loss is neither due to necrosis nor apoptosis. They also 
found increased numbers of cells that express the EMT markers Snail and S 1 00A4 
and suggested that this phenomenon contributes to hepatocarcinogenesis in a 
paracrine signaling manner. For instance, Snail expression is known to repress E­
cadherin expression which will decrease intercellular adhesion and increase 
cellular detachment. 
The mechanism proposed by Lennerz et al may also represent the 
underlying mechanism of the loss of ductules in our HCC samples although the 
87 
Chapter 4 
precise relationship between the possible ductular phenotypic switch with the 
presence of microvascular invasion remains to be elucidated. 
The results of the present study and those of Lennerz et al showed the 
significance of the peritumoral area in hepatocarcinogenesis and invasive growth 
and corroborate the significance of the tumor microenvironment in cancer 
progression as has been outlined in recent reviews [9, 12]. 
From a diagnostic practical perspective our translational finding from gene 
expression levels into altered patterns of histological structures may lead to 
improvements of predicting micro-VI in HCC before surgery. Biopsies of HCC 
present in a cirrhotic liver that contain both PT and D septa will allow a similar 
comparative evaluation as described in this study. Together with other predictive 
parameters this evaluation may increase the reliability of predicting micro-VI as 
none of the reported predictive parameters contains reliably high predictive values 
that may justify therapeutic implications on a single parameter [5]. Robust 
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Novel therapeutic strategies are needed to treat for patients with advanced 
hepatocellular carcinoma (HCC). Combination therapy of sorafenib and type I 
interferon (I FN) has substantial activity in patients with metastatic renal cell 
carcinoma. We investigated the antiproliferative effects of sorafenib in combination 
with pegylated interferon-a2b (PEG-IFN-a2b) on human hepatocellular carcinoma 
(HCC) cells in vitro and in vivo. A poorly differentiated HCC cel l  line derived from a 
patient with hepatitis C virus infection, HAK-18, and a moderately differentiated 
HCC cell line, KIM-1, were used in this study. We demonstrated the synergistic 
antiproliferative effect of combination therapy on HAK-1 B cells in vitro. In the in vivo 
study, the significant reduction of tumor volume and weight were observed in the 
combination group in both HAK-18 and KIM1 tumors, although synergistic effects 
were not clearly seen. CD34-positive-microvessel density was significantly lower 
and cleaved caspase-3-positive apoptotic cell number higher, in the sorafenib 
group and the combination group compared to control or PEG-IFN-a2b group in 
both HAK-18 and KIM-1 tumors. Ki67 labeling index was significantly lower in the 
combination group than in the control group in KIM-1 tumors. In conclusion, our 
results suggest that the combination therapy may be more effective for the 
treatment of HCC cases with variable sensitivity to anti-tumor effects of single 




Primary liver cancer, of which hepatocellular carcinoma (HCC) represents the 
major subtype accounting to between 85% and 90%, is the six th most common 
tumor globally, and the third most common cause of cancer-related death (1 ). 
Systemic treatment options for advanced HCC are limited and most deaths occurr 
within 1 year of diagnosis (2-4). 
Sorafenib is an oral multikinase inhibitor that was approved by the U .S. 
Food and Drug Administration in December 2005 for the treatment of advanced 
renal cell carcinoma (RCC) and in November 2007 for the treatment of HCC. It has 
been shown to inhibit the activity of Raf kinase and several receptor tyrosine 
kinases, including vascular endothelial growth factor receptors (VEGFR)-1, 2, and 
3 ,  platelet-derived growth factor receptor (PDGFR)- a and �, FL T3 , Ret and c-Kit. 
The intracellular signaling pathway Raf/ME K/E R K  and the extracellular receptors 
VEGFR and PDGFR have been implicated in the molecular pathogenesis of HCC 
(5) . 
The Sorafenib Hepatocellular Carcinoma Assessment Randomized 
Protocol (SHAR P) trial revealed efficacy of sorafenib in the treatment of HCC, i.e. , 
both median survival and time to progression showed 3-month improvements by 
sorafenib therapy (6). Cheng et a l  (7) also reported the efficacy of sorafenib in 
patients in the Asia- Pacific region with advanced hepatocellular carcinoma in 2009. 
Combination therapy with sorafenib has a potential to improve the outcome of 
sorafenib monotherapy. Phase I I  trial of combination therapy of sorafenib and IFN­
a has substantial activity in patients with metastatic RCC (8 ,9). The combination 
therapy of IFN-a and 5-fluorouracil is partly or completely effective in about 50% of 
the patients with advanced HCC (10) . Type I interferon ( IFN) has various effects, 
including anti-viral effects ,  anti-proliferative effects and anti-angiogenic effects (11 ) ,  
and our laboratory previously reported the antiproliferative effect of IFN-a on 
human liver cancer cells in vitro and in vivo (12-14) . In addition, type I IFN has 
suppressive effects on the occurrence of HCC, and the recurrence of HCC after 
curative treatment in patients with chronic hepatitis C virus infection (15-20). On the 
basis of above-described background, our current study examined the growth 
inhibitory effects of combination treatment of sorafenib and Pegylated IFN a-2b 
(PEG-IFN-a2b) on human HCC cell lines in vitro and in vivo. 
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Materials and methods 
Cell line and cell cultures 
This study used two HCC cell lines (KIM-1 (21) and HAK-1 B (22)), which were 
originally established and characterized in our laboratory and previously confirmed 
to retain morphological and functional characteristics of the original tumor. Both of 
these two cell lines were established from surgically resected HCC nodules. KIM-1 
is a moderately differentiated HCC cell line, and HAK-1 B is a poorly differentiated 
HCC cell line which was derived from a patient with hepatitis C virus (HGV) 
infection. The cells were grown in Dulbecco's Modified Eagle Medium (Nissui 
Seiyaku Co., Tokyo, Japan) supplemented with 2.5% heat-inactivated (56°C, 30 
min) fetal bovine serum (FBS, Bioserum, Vic, Australia), 100 U/ml penicillin, 100 
mg/ml streptomycin (GIBCO BRL/Life Technologies Inc., Gaithersburg, MD) and 12 
mmol/1 sodium bicarbonate, in a humidified atmosphere of 5% CO2 in air at 37°C. 
Sorafenib and pegylated IFNa-2b 
Sorafenib, kindly provided by Bayer Pharmaceutical Corporation (West Haven, CT), 
was dissolved in dimethyl sulfoxide (DMSO) to create a 10 mM stock solution and 
stored at -20°C for in vitro study. For in vivo study, we prepared the solution at time 
of use. PEG-IFN-a2b (PEG lntron®) was kindly provided by MSD K.K. (Tokyo, 
Japan). The specific activity of PEG-IFN-a2b was 6.4x107 IU/mg protein. 
Effect of sorafenib alone or combination treatment of sorafenib and PEG-IFN-a2b 
on the proliferation of HCC and CHC cell lines in vitro 
The effects of sorafenib and/or PEG-IFN-a2b on the growth of the cultured cells 
were examined with colorimetry using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay kits (Chemicon International Inc.) as described 
elsewhere (12-14). Briefly, the cells (1.5-5.5x103 cells per well) were seeded on 
ninety-six-well plates (Nunc Inc. , Roskilde, Denmark), cultured for twenty-four 
hours, and the culture medium was changed to a new one containing 0.2% DMSO 
(control) or Sorafenib (0.3125, 0.625, 1.25, 2.5, 5, 10 or 20 µM), or both sorafenib 
(0, 1.25, 2.5 or 5 µM) and PEG-IFN-a2b (0, 2,000, 4,000, 8,000 IU/ml) (constant­
ratio combination). After culturing for 72 hours, the number of viable cells was 
measured with lmmunoMini NJ-2300 (Nalge Nunc International, Tokyo, Japan) by 
setting the test wavelength at 570 nm and the reference wavelength at 630 nm. To 
keep the optical density within linear range, all experiments were performed while 
the cells were in the logarithmic growth phase. 
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Combination analysis was performed by using the method as described by Chou 
and Talalay (23) , and the CalcuSyn software program (Biosoft, Cambridge , U K) for 
automated analysis. This program calculates the combination index (Cl). A Cl of 
0.9 - 1 .1 indicates a nearly additive effect , a Cl of less than 0.9 a synergistic effect , 
a Cl of more than 1.1 an antagonistic effect. 
Morphological observation 
For morphological observation under a light microscope , cultured HAK-1 B cells 
were seeded on Lab-Tek tissue culture chamber slides (Nunc Inc.), cultured with or 
without 1.25 µM of sorafenib for seventy-two hours , fixed for ten minutes in 
Carnoy's solution , and stained with hematoxylin-eosin (HE). 
Quantitative analysis of apoptotic cells induced by sorafenib and/or PEG- IFN-a2b 
HAK-1 B and K I M-1 were cultured with the culture medium containing 0.02% DMSO 
or 2 µM of sorafenib for seventy-two hours. For a study of  combination therapy , 
HAK-1 B cells were cultured with sorafenib (1.25 µM) or PEG- IFN-a2b (2 ,000 I U/ml) , 
or both sorafenib (1.25 µM) and PEG- IFN-a2b (2 ,000 I U/ml) for seventy-two hours. 
After incubation , the cells were stained with the Annexin V-EGFP (enhanced green 
fluorescent protein) using Apoptosis Detection Kits (Medical & Biological 
Laboratories , Nagoya , Japan) according to the manufacturer's protocol. After 
staining , the cells were analyzed using a FACScan (Becton Dickinson 
lmmunocytometry Systems , San Jose ,  CA), and the rate of Annexin V- EGFP­
positive apoptotic cells was determined. 
Effects of sorafenib and/or PEG- IFN-a2b on HCC cell proliferation in nude mice 
This experiment was approved by the institutional committee for animal 
experiments and conducted according to the 'Guide for the Care and Use of 
Laboratory Animals' published and revised by the National Institute of Health in 
1985. 
Cultured HAK-1 B or K IM-1 cells (1.0x106 cells/mouse) were transplanted 
subcutaneously (sc) to four-week-old female BALB/c athymic nude mice (Clea 
Japan Inc. , Osaka , Japan). On the seventh day when tumor size became five to 
ten mm in diameter (Day 0) , the mice were divided into four groups (n=8 each) in a 
manner to equalize the mean tumor diameter of every group. Each group was 
assigned to one of the four treatments : (A) control; (B) PEG- IFN-a2b alone ; (C) 
sorafenib alone ; (D) sorafenib + PEG- IFN-a2b (combination). 
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Sorafenib was diluted with 12.5% Cremophor EL/ 12.5% ethanol/ 75% 
water for oral dosing in mice. Sorafenib (200 µg/day) was administered by tube 
feeding once a day for fourteen days. PEG-IFN-a2b (1 1920 IU) was 
subcutaneously injected twice a week for fourteen days (Day 1 1 Day 4 1 Day 8 1 and 
Day 11 ). In the control and the sorafenib alone groups, 0.1 ml of medium as the 
replacement of PEG-IFN-a2b was injected subcutaneously twice a week. In the 
control and the PEG-IFN-a2b alone groups, 0.2 ml of Cremophor EL/Ethanol/Water 
(12.5/12.5/75) as the replacement of sorafenib was administered by tube feeding 
once a day. The dose of sorafenib (200 µg) in the ratio to the average bodyweight 
of a mouse (20 g) was 10 mg/kg and this is almost comparable to a clinical dose 
(800 mg total daily dose). The clinical dose of PEG-IFN-a2b in chronic hepatitis C 
is 96,000 IU/kg per week. Because of species difference and different target which 
is not virus, but tumor, we used twice the dose per week in nude mice. 
Tumor size was measured in two directions using calipers, and tumor 
volume (mm3) was estimated by using the equation: length x (width)2 x 0.5. This 
measurement was performed every two days. Mouse body weight was measured 
on Day 0, Day 7, and Day 14. Mouse was sacrificed and the tumor was resected 
on the next day after the completion of this fourteen day treatment (Day 15). The 
resected tumor was fixed in formalin after the weight measurement 1 prepared into 
paraffin sections 1 and underwent HE staining and immunohistochemistry. 
I mmunohistochemistry 
Paraffin-embedded tissue samples were cut into four-micro meter sections. Anti­
mouse CD34 (Rat monoclonal 1 MEC14.7 1 Abcam 1 Cambridge 1 UK) (1 :50 dilution) 
and Ki67 (Rabbit monoclonal, SP6, Abeam, Cambridge 1 UK) (1: 100 dilution) 
staining were performed by standard avidin-biotin-peroxidase complex method and 
3,3'-diaminobenzidine (DAB) solution was used for color development. Cleaved 
caspase-3 (rabbit polyclonal antibody, Cell Signaling Technologies, Beverly, MA, 
USA) (1 :250 dilution) staining was performed on the Discovery XT automated 
staining system (Ventana Medical Systems, Tucson, AZ, USA) to detect the 
apoptotic cells. This automated system uses the streptavidin-biotin complex 
method with DAB as a chromogen (Ventana iVIEW DAB Detection KIT). 
Microvessel density (MVD) was evaluated within the tumor according to a 
modified method introduced by Tanigawa et al (24). Briefly the slides stained with 
CD34 were screened at low power field (x40 or x100) and the two or three most 
vascular areas were selected. Microvessel counts of these areas were performed 
at high power field (x200, 0.74 mm2). All positive stained cells were counted as 
microvessels and every 40 µm length of vessel lumen was calculated as one point. 
The average microvessel counts of selected areas were regarded as MVD, which 
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was expressed as the absolute number of microvessels per 0 .74 mm2. 
lmmunohistochemically, cleaved caspase-3 was expressed perinuclearly and Ki67 
was on nuclear . The rate of apoptotic cells and Ki67 labeling index were evaluated 
by calculating the rate of cleaved caspase-3-positive cells and Ki67-positive cells, 
respectively . 
Statistical analysis 
Comparisons of estimated tumor volume and colorimetric cell growth were 
performed using two-factor factoria l ANOVA and Student's t-test, respectively. The 




Effect of sorafenib alone or combination treatment of sorafenib and PEG-IFN-a2b 
on the proliferation of HAK-1 B or KIM-1 HCC cells in vitro 
Seventy-two hours after the addition of sorafenib, the relative viable cell number 
was suppressed in both HAK-1 B and KIM-1 cell lines in a dose-dependant manner 
(Fig. 1 ). The 50% inhibitory concentration (IC50) was 2.1 µM for HAK-1 B and 2.5 
µM for KIM-1. 
Seventy-two hours after the addition of PEG-IFN-a2b and sorafenib, the relative 
viable cell number was suppressed to various degrees. The results are exhibited in 
Fig. 2. In HAK-1 B cell line (Fig. 2A), significant difference in the relative viable cell 
number was observed between combination group and sorafenib or PEG-IFN-a2b 
alone groups, additionally, Cl in all combination of PEG-IFN-a2b and sorafenib was 
less than 0.9. The Cl was 0.879 in the combination of 2,000 IU/ml of PEG-IFN-a2b 
and 1.25 µM of sorafenib, 0.667 in 4,000 IU/ml of PEG-IFN-a2b and 2.5 µM of 
sorafenib, and 0.842 in 8,000 IU/ml of PEG-IFN-a2b and 5.0 µM of sorafenib. 
According to the definition of the Cl, these results indicate that a combination of 
PEG-IFN-a2b and sorafenib may produce a synergistic growth inhibitory effect in 
HAK-1 B cell line. In KIM-1 cell line (Fig. 2B), there was also a significant difference 
in the relative viable cell numbers between combination group and monotherapy 
groups. The Cl was 0.912 in the combination of 2,000 IU/ml of PEG-IFN-a2b and 
1.25 µM of sorafenib, 0.992 in 4,000 IU/ml of PEG-IFN-a2b and 2.5 µM of 
sorafenib, and 0.823 in 8,000 IU/ml of PEG-IFN-a2b and 5.0 µM of sorafenib. 
These results indicate that combination therapy may produce an additive or 
synergistic growth inhibitory effect in KIM-1 cell line. 
Morphologically, HAK-1 B cells showed characteristic features of apoptosis, 
such as cytoplasmic shrinkage and nuclear chromatin condensation at seventy-two 
hours after adding 1.25 µM of sorafenib (Fig. 3). 
The rate of Annexin V-EGFP positive apoptotic cells was increased by 
adding 2 µM of sorafenib in HAK-1 B cells (5.8% of the control and 37.8% of the 
sorafenib). In KIM-1 cells, however, the increase was relatively small (7.9% of the 
control and 9.5% of the sorafenib) (Fig. 4A). In another setting, the combination 
group with PEG-IFN-a2b showed higher rate of apoptosis than control or 
monotherapy groups in HAK-1 B (4.8% of control, 37.4% of the PEG-IFN-a2b, 
14.3% of the sorafenib, 42.8% of the combination) (Fig. 4B). 
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Figure 1 .  Seventy-two hours after adding 0.31 25, 0.625, 1 .25, 2 .5, 5, 1 0  or 20 µM of sorafenib. Cell 
prol iferation was suppressed in a dose-dependant manner in both KIM-1 and HAK-1 B cell lines. The 
suppression was sign ificant (P<0.001 -0.05) in the range of 0.625-20 µM of sorafenib in KIM-1 , 1 .25-20 
µM in HAK-1 B. 50% g rowth inh ibitory dose was 2 .5  µM in KIM-1 and 2 . 1  µM in HAK-1 B. The values 
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Figure 2. Effect of PEG-IFN-a2b and/or sorafenib on the proliferation of human HCC cell lines HAK-1 B 
(A) and KIM-1 (B) in culture for 72 hours. Light gray bars are PEG-IFN-a2b alone group, dark gray bars 
sorafenib alone group, and black bars PEG-IFN-a2b + sorafenib group. All combination groups showed 
sign ificant difference compared with monotherapy g roups. The n umbers above bars are Cl .  A Cl of 0.9 
- 1 . 1 indicates a nearly additive effect, a Cl of less than 0 .9 a synergistic effect, a Cl of more than 1 . 1 
an antagonistic effect. Representative data of two independent experiments were shown. The values 
represent mean ± SD. 
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Figure 3. Photomicrograph of HAK-1 8 cells cultured for seventy-two hours on Lab-Tek Chamber slide. 
(A) Without sorafenib in culture medium. Some mitotic figures were noted (arrow heads). (8) With 1 .25 
µM of sorafenib in culture medium. There were some apoptotic cells characterized by cytoplasmic 
shrinkage and nuclear chromatin condensation (arrows). 
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Figure 4. Quantitative analysis of  Annexin V-EGFP positive apoptotic cells. (A) Apoptosis of  HAK-1 B or  
KIM-1 cells induced by  2 µM of  sorafenib. (8) Apoptosis of HAK-1 B cells induced by  2 ,000 IU/ml of 
PEG-IFN-a2b and/or 1 .25 M of sorafenib. Representative data of three independent experiments were 
shown. 




Chronological changes in estimated tumor volume after subcutaneous injection of 
cultured HAK-1 B cells or KIM-1 cells to nude mice are summarized in Fig. 5. The 
actual tumor weights at the time of sacrifice are exhibited in Table 1. In the 
experiment of HAK-1 B tumors, the tumor volume of mice receiving PEG-IFN-a2b, 
sorafenib, and sorafenib+PEG-IFN-a2b was 34%, 73%, and 36%, respectively, of 
the control volume and the tumor weight was 23%, 71 %, and 34%, respectively, of 
the control weight. Statistically, there were significant differences both in tumor 
volume and weight between the control group and the PEG-IFN-a2b alone group 
(P<0.0001 versus control in tumor volume, P<0.0001 versus control in tumor 
weight) or the combination group (P<0.0001 versus control in tumor volume, 
P<0.001 versus control in tumor weight) and between the sorafenib alone group 
and the PEG-IFN-a2b alone group (P<0.005 versus sorafenib alone in tumor 
volume, P<0.05 versus sorafenib alone in tumor weight). Although there was a 
significant difference between the sorafenib alone group and the combination 
group in tumor volume (P<0.001 ), there was not in actual tumor weight (P=0.099). 
In the experiment of KIM-1 tumors, the tumor volume of mice receiving PEG-IFN­
a2b, sorafenib, and sorafenib+PEG-IFN-a2b was 69%, 45%, and 46%, 
respectively, of the control volume and the tumor weight was 75%, 41 %, and 37%, 
respectively, of the control weight. Statistically, there were significant differences in 
both tumor volume and weight between the control and the sorafenib alone group 
(P<0.0001 versus control in tumor volume, P<0.05 versus control in tumor weight) 
or the combination group (P<0.001 versus control in tumor volume, P<0.05 versus 
control in tumor weight). 
The results of immunohistochemical examination are summarized in Table 
2. The significant decrease of MVD and increase of apoptotic cells were observed 
in the sorafenib group (P<0.0005 and 0.05 respectively versus control in HAK-1 B, 
P<0.05 and 0.05 respectively versus control in KIM-1) and the combination group 
(P<0.05 and 0.05 respectively versus control in HAK-1 B, P<0.05 and 0.05 
respectively versus control in KIM-1) compared to the control group in both HAK-
1 B and KIM-1 tumors, although there was no significant difference between the 
combination group and monotherapy groups. Ki67 labeling index was significantly 
lower in the combination group (P<0.005 versus control, P<0.05 versus PEG-IFN­
a2b group) than in the control group or the PEG-IFN-a2b group only in KIM-1. 
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Figure 5. Chronological changes on the estimated volume of HAK-1 8 (Experiment 1 )  or KIM-1 
(Experiment 2) tumor that was developed subcutaneously on nude mice. The PEG-IFN-a2b alone group 
(•) received subcutaneous injection of 1 ,920 IU twice a week for 14  days. The sorafenib alone group 
( •)  received 1 0 mg/kg/mouse/day orally every day for 14 days. The PEG-IFN-a2b + sorafenib group ( ♦) 
received 1 ,920 IU  of PEG-IFN-a2b twice a week and 10 mg/kg of sorafenib every day for 14  days. The 
control group (■) received subcutaneous injection of 0. 1 ml of medium twice a week and 0 .2 ml of 
Cremophor EUEthanol/Water (1 2.5/1 2 .5/75). The values represent mean ± SE. *P<0.05 versus control. 
tP<0.0001 versus control, P<0.005 versus sorafenib alone. :t:P<0.0001 versus control, P<0.001 versus 
sorafenib a lone. §P<0.001 versus control. I IP<0.0001 versus control. 
Table 1 .  The weight of subcutaneous tumor of HAK-1 B cells or KIM-1 cells in nude mice at sacrifice. 
Treatment group 
Tumor weight (g) 
HAK-1 B KIM-1 
Control 0 .333 ± 0.03 0.504 ± 0. 1 7  
PEG-IFN-a2b alone 0.078 ± 0 .02 * 0.379 ± 0. 1 8  
Sorafenib alone 0.236 ± 0.06 0.206 ± 0.04 *** 
PEG-IFN-a2b + sorafenib 0 . 1 1 3  ± 0.04 ** 0. 1 85 ± 0 . 1 2  *** 
Tumor weight represents mean ± SE (g). * P<0.0001 versus control, P<0.05 versus sorafenib alone. ** 
P<0.001 versus control. *** P<0.05 versus control. 
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Table 2. MVD and the ratio of apoptotic cells and Ki67 positive cells in human HCC tumors 




Treatment group MVD 
Control 1 00.8 ± 7.7 
Peg-lFN-a2b alone 1 1 4.9  ± 1 6.7 
Sorafenib alone 53.8 ± 4.3 * 
Peg- lFN-a2b+soragfenib 69.4 ± 1 0. 1  ** 
Control 1 25.9 ± 1 6.2 
Peg-lFN-a2b alone 97.4 ± 1 0 .4 
Sorafenib alone 85. 1 ± 6.6 ** 
Apoptotic cells 
3.8 ± 0.4 
4.4 ± 0.4 
6.7 ± 1 .3 ** 
5.6 ± 1 .3 ** 
4.6 ± 0.4 
5.1 ± 0.4 
6.5 ± 0.7 ** 
Ki67 positive cel ls 
36.8 ± 2.0 
37.5 ± 4.6 
38.3 ± 2.0 
35.3  ± 2.2 
6.7 ± 0.2 
7.5 ± 0.8 
5.7 ± 0.4 
Peg-lFN-a2b+soragfenib 79.0 ± 7.2 ** 6 .3 ± 0.6 ** 4.6 ± 0.5 *** 
Scores represent mean ± SE. * P<0.0005 versus control, P<0.01  versus Peg-lFN-a2b alone. ** P<0.05 




In this study, we showed the synergistic effect of sorafenib and PEG-IFN-a2b on 
HAK-1 B cells in vitro. We previously reported that PEG-IFN-a2b induced apoptosis 
on both HAK-1 B and KIM-1 cells in vitro (14). We found that sorafenib also induced 
apoptosis on HAK-1 B in vitro. On the other hand, the increase of apoptotic cells 
was not clearly observed on KIM-1 cells in spite of the fact that the proliferation of 
KIM-1 cells was inhibited by sorafenib in MTT assay. A possible explanation is that 
cell proliferation might be inhibited by other anti-proliferative mechanisms. The 
blockade of Raf signaling which is main effect of sorafenib can lead to the 
repression of transforming growth factor a-epidermal growth factor receptor 
autocrine loops of tumor cells (5). Such a mechanism could have inhibited the 
growth of KIM-1 cells. In addition, a limitation of in vitro study is that we are not 
able to assess the indirect anti-angiogenic effect against endothelial cells. 
In the in vivo study, there was a significant reduction of tumor volume and 
weight in the combination group on both HAK-1 B and KIM-1 tumors compared with 
the control group. However there was no significant difference between the 
combination and the monotherapy groups, and it seemed that HAK-1 B tumors 
were sensitive to PEG-IFN-a2b and KIM-1 tumors to sorafenib. Only in KIM-1 
tumors that might be sensitive to sorafenib, Ki67 labeling index was lower in the 
combination group than in the control group. Recently Wang et al (25) reported that 
combination therapy of sorafenib with recombinant human INF-a2a was effective in 
vitro and in vivo on two HCC cell lines, Huh-7 and Sk-Hep-1. In their study, the 
significant differences between combination and monotherapy groups were clearly 
observed. This partial difference might be due to the different experimental settings, 
such as different cell lines and different dose of drugs. One of the biggest 
differences, we surmise, is the site of IFN administration. They injected IFN directly 
into subcutaneous tumors, whereas we did subcutaneously but not into the tumors. 
Since sorafenib is a multikinase inhibitor, it is considered that sorafenib 
has both direct anti-proliferative effect due to the blockade of Raf kinase on tumor 
cells themselves and indirect effect due to the blockade of receptor tyrosine 
kinases, such as VEGFR-2, on endothelial cells followed by the inhibithion of 
angiogenesis (5). Therefore we also evaluated MVD of xenografts and confirmed 
the significant decrease of MVD in the sorafenib alone and the combination group 
in both HAK-1 B and KIM-1 tumors. It has been repeatedly shown that IFN 
suppress the growth of the various types of human tumor that was transplanted to 
mice through the anti-angiogenic effect. For instance, Tedjarati et al (26) reported 
that the subcutaneous injection of 7,000 IU per week of PEG-IFN-a2b into nude 
mice bearing human ovarian cancer cells induced the significant decrease of CD31 
positive endothelial cells and Huang et al (27) also showed the similar results with 
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the subcutaneous injection of 70,000 IU per week of PEG-IFN-a2b on human 
prostate cancer cells. PEG-IFN-a2b administered at higher or lower doses was 
less effective. In our current study, however, there was no significant decrease of 
MVD in the PEG-IFN-a2b group compared with the control group. Moreover, in our 
previous report, the decrease of artery-like blood vessels was not observed in the 
same HAK-1 B tumors by the administration of PEG-IFN-a2b at either higher or 
lower doses (14). 
Another notable finding regarding to MVD in this study is the discrepancy 
between MVD and tumor weight or size. Interestingly, the reduction of tumor weight 
and size was not so much in sorafenib monotherapy group in HAK-1 B tumors 
despite the most prominent decrease of MVD was observed in this group. On the 
other hand, there was a significant reduction of tumor weight and size in PEG-IFN­
a2b alone group in HAK-1 B, although this group did not show any significant 
decrease of MVD. This result supports our previous findings in which we showed 
there was no relationship between tumor shrinkage and the number of artery-like 
blood vessels in HAK-1 B tumors after the administration of the various 
concentration of PEG-IFN-a2b (14). Hlatky et al (28) mentioned in their review 
article that the efficacy of anti-angiogenic agents cannot be simply visualized by 
alterations in microvessel density during treatment because of the difference of the 
tightness of the coupling between vessel dropout and tumor-cell dropout after the 
treatment. In addition, Yao et al (29) recently reported that the expression of 
VEGFR-1 in tumor cells which is normally expressed specifically in endothelial cells 
were strongly associated with anti-PIGF antibodies efficacy, but not with 
antiangiogenesis. More studies are needed to investigate more appropiate ways to 
assess the efficacy of anti-angiogenic drugs in vivo and molecular mechanisms of 
their action of "anti-angiogenic" drugs. 
In conclusion, we demonstrated the synergistic antiproliferative effect of 
combination therapy on HAK-1 B cells in vitro. Although, in vivo study, synergistic 
effects of the combination therapy were not clearly observed, the combination 
therapy induced nearly maximum anti-tumor effects, independent of the HCC cells' 
sensitivity to anti-tumor effects of single therapy with either PEG-IFN-a2b or 
sorafenib. These findings suggest that PEG-IFN-a2b might be a promising 
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Purpose: We investigated the effects of pegylated interferon-a2a (PEG-IFN-a2a) 
on the growth of human liver cancer cells. 
Methods: The effect of PEG-I FN-a2a on the proliferation of 13 liver cancer cell 
lines was investigated in vitro. Cells were cultured with medium containing 0-4, 194 
ng/ml of PEG-IFN-a2a, and after 1, 2, 3, or 4 days of culture, morphologic 
observation and growth assay were performed. After hepatocellular carcinoma 
(HCC) cells (HAK-1 B and KIM-1) were transplanted into nude mice, various doses 
of PEG-I FN-a2a were subcutaneously administered to the mice once a week for 2 
weeks, and tumor volume, weight, and histology were examined. 
Results: PEG-IFN-a2a inhibited the growth of 8 and 11 cell lines in a time- and 
dose-dependent manner, respectively, although the 50% growth inhibitory 
concentrations of 7 measurable cell lines on Day 4 were relatively high and ranged 
from 253 ng/ml to 4,431 ng/ml. Various levels of apoptosis induction were 
confirmed in 8 cell lines. PEG-I FN-a2a induced a dose-dependent decrease in 
tumor volume and weight, and a significant increase of apoptotic cells in the tumor. 
Subcutaneous administration of clinical dose for chronic hepatitis C (3 µg/kg, 0.06 
µg/mouse) was effective and induced about 30-50% reduction in the tumor volume 
and weight as compared with the control. 
Conclusions: Although in vitro anti-proliferative effects of PEG-IFN-a2a were 
relatively weak, PEG-IFN-a2a induced strong anti-tumor effects on HCC cells in 
vivo. The data suggest potential clinical application of PEG-IFN-a2a for the 




Interferons (IFNs) are types of cytokine that are produced by host cells, such as 
leukocytes, in response to inflammation. Since IFNs possess antiviral activity, 
antiproliferative activity and various immunoregulatory activities, IFN therapy is 
used to treat patients with chronic viral hepatitis or certain types of cancer including 
malignant melanoma, acquired immunodeficiency syndrome-related Kaposi's 
sarcoma and some hematopoietic malignancies [1, 2]. Lai et al also showed that 
recombinant IFNa is useful in prolonging survival among patients with inoperable 
hepatocellular carcinoma (HCC) [3]. In addition, some studies showed IFN therapy 
might prevent either occurrence or recurrence after initial curative therapy of HCC, 
such as liver resection and radiofrequency ablation, in patient with chronic viral 
hepatitis [4-7]. This cancer preventive effect of IFNs is regarded mainly as results 
of their antiviral effect and the consequent suppression of inflammation, and might 
be due to their direct antitumor effect against clinically undetectable HCC as well. 
The detailed mechanism of the antitumor effect of I FNs, however, remains obscure. 
Pegylated interferon-a2a (PEG-IFN-a2a) and pegylated interferon-a2b 
(PEG-IFN-a2b), which are used to treat patients with chronic hepatitis C virus 
(HCV) or B virus (HBV) infection, are modified IFNs that have longer serum half-life 
in body than non-pegylated forms of IFNs, therefore they can be given to patients 
only once a week, whereas a standard IFN without pegylation used to be injected 
up to three to five times a week. This once-a-week injection of pegylated IFNs in 
combination with daily oral dosing of the nucleoside analogue ribavirin has 
substantially improved the rate of sustained virological response in patients with 
chronic HCV infection and got a position as the first line therapy [8, 9]. We 
previously reported that PEG-IFN-a2b which contains 12 kDa polyethylene glycol 
(PEG) has stronger antitumor effects in vivo than non-pegylated IFNs and this 
result might be indicating that continuous IFNs exposure to cancer cells in body is 
more effective than continual injection [1 O]. On the basis of above-described 
background, we examined the growth inhibitory effects of PEG-IFN-a2a which 
contains two chains of 20 kDa PEG and has the longest serum half-life among 
clinically available IFNs on liver cancer cell lines in vitro and in vivo. 
Methods 
Cell Lines and Cell Culture 
This study used 11 HCC cell lines (KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, HAK-
1 B, HAK-2, HAK-3, HAK-4, HAK-5, and HAK-6) and 2 human combined 
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hepatocellular and cholangiocarcinoma (CHC) cell lines (KMCH-1 and KMCH-2). 
These HCC and CHC cell lines were originally established in our laboratory, and 
each cell line retains the morphological and functional features of the original tumor 
as described elsewhere [11-20]. 
The cells were grown in Dulbecco's Modified Eagle Medium (Nissui Seiyaku, 
Co. , Japan) supplemented with 2.5% heat-inactivated (56°C, 30 min) fetal bovine 
serum (FBS, Bioserum, Victoria, Australia), 100 U/ml penicillin, 100 µg/ml 
streptomycin (GIBCO BRL/Life Technologies, Inc., Gaithersburg, MD) and 12 
mmol/L sodium bicarbonate, in a humidified atmosphere of 5% CO2 in air at 37°C. 
I FN and Reagents 
PEG-IFN-a2a (PEGASYS®, Chugai Pharmaceutical Co. , Ltd., Tokyo, Japan) with 
the specific activity of 1.4 X 107 IU/mg protein and non-pegylated IFN-a2a (Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) with that of 2.0 X 108 IU/mg protein 
were used in the study. 
Anti-bromodeoxyuridine (BrdU) antibody and fluorescein isothiocyanate­
conjugated goat anti-mouse immunoglobulin (FITC-GAM) were purchased from 
Becton Dickinson lmmunocytometry Systems USA (San Jose, CA); control normal 
mouse lgG 1 , from DAKO (Glostrup, Denmark); rat antibody against mouse 
endothelial cells (anti-CD34, clone MEC14.7), from Serotec Co. , UK; and mouse 
monoclonal antibody against human a-smooth muscle actin (SMA) that cross­
reacts with mouse a-SMA (clone 1A4). 
Effects of PEG-IFN-a2a on the Proliferation of HCC and CHC Cell Lines in vitro 
The effects of PEG-IFN-a2a on the growth of the cultured cells were examined with 
colorimetry using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay kits (Chemicon, Temecula, CA) as described elsewhere [18, 21 ]. 
Briefly, the cells (1.5~8 X 103 cells per well) were seeded on 96-well plates (Nunc, 
Inc, Roskilde, Denmark), cultured for 24 hours, and the culture medium was 
changed to a new medium with or without PEG-IFN-a2a (0.016, 0.064, 0.256, 
1.024, 4.096, 16.4, 65.5, 262, 1,048, or 4,194 ng/ml). After culturing for 24, 48, 72 
or 96 hours, the number of viable cells was measured with lmmunoMini NJ-2300 
(Nalge Nunc International, Tokyo, Japan) by setting the test wavelength at 570 nm 
and the reference wavelength at 630 nm. To keep the optical density within linear 
range, all experiments were performed while the cells were in the logarithmic 
growth phase. 
Quantitative analysis of apoptotic cells induced by PEG-IFN-a2a 
HAK-1 B or KIM-1 cells cultured with medium alone (control), non-pegylated IFN­
a2a (10 ng/ml=2,000 IU/ml) or PEG-IFN-a2a (144 ng/ml=2,000 IU/ml) for 72 hours 
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were stained with the Annexin V-EGFP (enhanced green fluorescent protein) 
Apoptosis Detection Kits (Medical & Biological Laboratories Co. ,  Ltd.) according to 
the manufacturer's instructions. After staining, the cells were analyzed using a 
FACScan (Becton Dickinson lmmunocytometry Systems, San Jose, CA), and 
Annexin V-EGFP-positive apoptotic cell rate was determined. 
Morphological Observation 
For morphological observation under a light microscope, cultured cells were 
seeded on Lab-Tek tissue culture chamber slides (Nunc, Inc.), cultured with or 
without PEG-IFN-a2a (262, 1,048 or 4,194 ng/mL) for 72 hours, fixed for 10 min in 
Carney's solution, and stained with hematoxylin-eosine (HE). 
Effects of PEG-IFN-a2a on HCC Cell Proliferation in Nude Mice 
All animal experiments were approved by the institutional committee for animal 
experiments in Kurume University School of Medicine (Permit Number: 1334), and 
conducted according to the Guide for the Care and Use of Laboratory Animals of 
the National Institute of Health and the Regulations for Animal Experimentation of 
Kurume University School of Medicine. Mice were killed by cervical dislocation 
under diethyl ether anesthesia, and all efforts were made to minimize suffering. 
Cultured HAK-1 B or KIM-1 (107 cells/mouse) was subcutaneously (s.c.) injected 
into the backs of 5-week-old female BALB/c athymic nude mice (Clea Japan, Inc., 
Osaka, Japan). Five to seven days later when the largest diameter of the tumor, 
which was measured by using caliper, reached approximately 5~10 mm (Day 0), 
tumor volume (mm3) was culculated in the equation 'the largest diameter X (the 
smallest diameter? X 0.5', and then the mice were divided into 5 groups (n=8 
each). The mean tumor volume of each group was equalized. Tumor volume was 
measured on Day 0, 1, 2, 4, 6, 8, 10, 12, and 14. Mouse body weight was 
measured on Day 0, 8, and 14. After 2-week treatment, mice were killed on Day 15 
and the actual tumor weight was also measured. In experiment #1, each mouse 
received a subcutaneous injection of 0.333 ml of phosphate-buffered saline (PBS) 
(Control), PBS containing 0.06, 0.6, 6 or 60 µg (840, 8,400, 84,000, or 840,000 IU, 
respectively) of PEG-IFN-a2a once a week for 2 consecutive weeks (Day 1 and 
Day 8). The clinical dose of PEG-IFN-a2a in chronic hepatitis C treatment is about 
3 µg/kg and is equivalent to the lowest dose (0.06 µg/mouse=840 IU/mouse) in this 
experiment. After killing, resected tumors were used for morphological studies (e.g., 
HE staining and immunohistochemistry) and Enzyme-linked immunosorbent assay 
(ELISA) analysis. Every mouse received an intraperitoneal injection of 1 mg of 
BrdU 30 min before killing. In experiment #2, to examine the difference between 
non-pegylated and pegylated IFNs, each mouse received a subcutaneous injection 
of 0.333 ml of PBS (Control), PBS containing 0.06 or 0.6 µg of PEG-IFN-a2a (840 
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or 8,400 IU, respectively), or PBS containing 0.0042 or 0.042 µg of IFN-a2a (840 or 
8,400 IU, respectively). In this experiment, tumor weights on Day 15 were 
compared among the groups. 
Morphological Examination of the Subcutaneous Tumors of Nude Mice 
The number of cells showing the characteristics of apoptosis (e.g. , cytoplasmic 
shrinkage, chromatin condensation, and nuclear fragmentation) was counted in at 
least three 0.25 mm2-areas within an HE-stained specimen, and the average 
number per area was obtained. The TUNEL technique (ApopTag® Peroxidase In 
Situ apoptosis Detection Kits, CHEMICON International, Inc, CA) was used to 
detect apoptotic cells, and the average number of TUNEL-positive cells per area 
was obtained, as described above. The specimens were also immunostained for 
incorporated Brd U using BrdU Staining Kits (Oncogene Research Products, Boston, 
MA), and the average number of positive cells per area was obtained as described 
above. In addition, double-immunostaining was performed with anti-mouse 
endothelial cell antibody, anti-human a-SMA antibody, Histofine simple stain 
mouse MAX-PO (Rat) kits (Nichirei, Tokyo, Japan), and HistoMouse™-plus kits to 
detect artery-like blood vessels as described in our previous report [21, 22]. The 
number of double-immunostaining-positive blood vessels in the tumor and in the 
borderline area between the tumor nodule and surrounding tissues was counted on 
each specimen. The size of the counted area was measured by tracing the outline 
displayed on a computer monitor using Mac SCOPE (MITANI  CORP., Chiba, 
Japan). From the obtained number of vessels per unit area (mm2) ,  the group mean 
was obtained for group comparison. 
Enzyme-linked immunosorbent assay (ELISA) 
Portions of the resected xenograft tumors were homogenized in 500 µ I  of ice-cold 
Ca2+ and Mg2+-free PBS containing 100 mg/ml phenymethylsulfonyl fluoride using 
a pellet pestle. The mixture was centrifuged for 10 min (12,000 g, 4°C), and the 
supernatant was stored at -20°C until use. After the determination of the amount of 
the tissue protein in the supernatant using a BCA protein assay reagent (Pierce, 
Rockford, IL), the amount of basic fibroblast growth factor (bFGF) and IL-8 was 
measured by using commercially available ELISA kits (R&D Systems, Minneapolis, 
MN). 
Statistics 
Comparisons of estimated tumor volume and colorimetric cell growth were 
performed using two-factor factorial ANOVA and Student's t-test, respectively. The 




Effects of PEG-IFN-a2a on Liver Cancer Cell Proliferation in vitro 
Twenty-four hours after the addition of 4,194 ng/ml of PEG-IFN-a2a, mild increase 
in the relative viable cell number occurred in 9 cell lines (all cell lines except KYN-2, 
HAK-1A, HAK-6, and KMCH-1). However, after 72 hours or later, a 10% or more 
decrease in the cell number occurred in all cell lines (Fig. 1A). In HAK-2, HAK-3, 
and HAK-4, HAK-6, and KMCH-2, proliferation was suppressed up to 72 hours and 
the cell number reached a plateau or slightly increased thereafter. In the other 8 
cell lines, proliferation was suppressed to varying degrees up to 96 hours. 
The relative viable cell number was suppressed in 11 cell lines (all cell lines 
except HAK-1A and KMCH-2) in a dose-dependent manner after the 96 hours­
incubation with PEG-IFN-a2a (Fig. 1 B). In 7 cell lines (HAK-1 B, KMCH-1, KIM-1, 
KYN-1, HAK-6, KYN-3, and KYN-2), the number was suppressed to 50% or less 
with 4,194 ng/ml of PEG-IFN-a2a, and the 50% inhibitory concentration (IC50) 
was 253 ng/ml for HAK-18, 670 ng/ml for KMCH-1, 1,105 ng/ml for KIM-1, 1,128 
ng/ml for KYN-1, 1,302 ng/ml for HAK-6 , 1,524 ng/ml for KYN-3, and 4,431 
ng/ml for KYN-2. No relationship was detected between the histological 
differentiation level of the original tumor and sensitivity to the anti-proliferative 
effect of PEG-IFN-a2a. 
Seventy-two hours after adding 4,194 ng/ml of PEG-IFN-a2a, 8 cell lines 
(all cell lines except KYN-3, HAK-1A, HAK-2, HAK-3, and KMCH-2) showed 
characteristics of apoptosis, e.g., cytoplasmic shrinkage, chromatin condensation, 
and nuclear fragmentation, in various degrees and in a dose-dependent manner 
(Fig. 2). The appearance of apoptosis was further confirmed in HAK-1 B and KIM-1 
cells cultured with 10 ng/ml (=2,000 IU/ml) of IFN-a2a or 144 ng/ml (=2,000 IU/ml) 
of PEG-IFN-a2a by apoptosis detection assay (Table 1 ). Non-pegylated IFN-a2a 
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Figure 1 .  Anti-proliferative effect of PEG-IFN-a2a. (A) Chronological changes in relative viable cell 
number (% of the control) after adding 4, 1 94 ng/mL of PEG-IFN-a2a. Growth was suppressed with time 
in 8 cell lines. (B) 96 hours after adding 1 0 d ifferent concentrations of PEG-IFN-a2a. Cell proliferation 
was suppressed in a dose-dependent manner in 1 1  cell lines. The suppression was significant (P < 
0.0001 ~0.05) in the ranges of 0.01 6~4, 1 94 ng/mL of PEG-IFN-a2a in HAK-6, 0.256~4, 1 94 ng/mL in 
KYN-3 and HAK-1A, 4.096~4, 1 94 ng/mL in KIM-1 , KYN-1 , HAK-1 B ,  HAK-2 and KMCH-2, 1 6.4~4, 1 94 
ng/mL in KYN-2, HAK-5 and KMCH-1 , 262~4, 1 94 ng/mL in HAK-4, and at 4, 1 94 ng/mL in HAK-3 
(Student t-test). Eight samples were used in each experiment (n = 8). The experiment was repeated at 
least 3 times for each cell l ine. The figures represent average ± SE of the experiments. 
Figure 2. Photomicrograph of HAK-1 B cells cultured for 72 hours on a Lab-Tek Chamber slide. (A) 
Without PEG-IFN-a2a in culture medium. (B) With 4, 1 94 ng/mL of PEG-IFN-a2a in culture medium. 
Apoptotic cells (short arrows) characterized by cytoplasmic shrinkage, chromatic condensation and 
nuclear fragmentation were noted (HE staining, X 200). 
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Table 1 .  Quantitative analysis of apoptosis in HAK-1 B or KIM-1 
Annexin V-EGFP apoptotic cells (%) 
Cell l ine8 Control IFN-a2a PEG-IFN-a2a 
HAK-1 8 4.1  ± 0 .5b 1 8.5 ± 0.3 1 0.9 ± 0.5 
KIM-1 9.4 ± 0.4 47.0 ± 0.2 29.8 ± 2 . 1  
Chapter 6 
a Cells were cultured with medium alone (Control), IFN-a2a (1 0 ng/ml=2,000 IU/ml) or PEG-IFN-a2a 
( 144 ng/ml=2,000 IU/ml). b Mean ±SE. 
Effects of PEG-IFN-a2a on HCC Cell Proliferation in Nude Mice 
Chronological changes in estimated tumor volume after subcutaneous injection of 
cultured HAK-1 B or KIM-1 cells to nude mice are summarized in Fig. 3. Dose­
dependent suppression of tumor volume was observed in mice receiving PEG-IFN­
a2a. In the experiment of HAK-1 B tumors, a significant difference in the changes in 
tumor volume and tumor weight was observed between the Control mice and the 
mice that received 0.06, 0.6, 6 or 60 µg of PEG-IFN-a2a (P < 0.0001 by two-factor 
factorial ANOVA; and P < 0.001 ~0.02 by the Mann-Whitney U test, Fig 3A and 
Table 2). In the experiment of KIM-1 tumors, a significant reduction of tumor 
volume was also observed with the use of PEG-IFN-a2a (P < 0.001 by two-factor 
factorial ANOVA, Fig 3B). There were significant differences in the actual tumor 
weight between the Control group and the PEG-IFN-a2a groups, except for the 
PEG-IFN-a2a (0.06 µg) group (Table 2). The actual tumor weight at the end of the 
experiment #2 was summarized in Table 3. Subcutaneous injection of 0.6 µg of 
PEG-IFN-a2a induced the significant reduction of tumor weight, compared with the 
Control group and the group that received the same international unit of non­
pegylated IFN-a2a (P<0.005 and P<0.03, respectively). In this experiment, there 
was no significant difference between the Control group and the PEG-IFN-a2a 
(0.06 µg) group (P=0.078). 
Histological examination of the HAK-1 B tumor specimens stained with HE 
revealed that the numbers of apoptotic cells in the mice treated with PEG-IFN-a2a 
(0.06 or 0. 6 µg) were significantly higher than that of the Control, and the number 
increased dose dependently (Fig. 4, A and B; Table 4). The incidence of apoptosis 
in TUNEL-stained sections showed the same tendencies as those obtained in HE­
stained sections (Fig. 4C and Table 4). lmmunohistochemical examination of BrdU 
uptake in HAK-1 B tumors revealed that there was no significant difference in BrdU 
labeling index between the Control and PEG-IFN-a2a (0.06 or 0.6 µg) groups 
(Table 4). 
There was a significant difference in the number of blood vessels per unit 
area within the HAK-1 B tumor between the Control mice and the mice that received 
0.06 µg of PEG-IFN-a2a (Fig. 5; Table 5). The number of blood vessels in the 
borderline area between the tumor nodule and surrounding tissues tended to be 
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higher in the mice treated with PEG-IFN-a2a (0.06 or 0.6 µg) than the Control mice. 
There was no significant difference in the expression of bFGF and IL-8 in 
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Figure 3. Time-course change in estimated tumor volumes of subcutaneously transplanted HAK-1 B (A) 
or KIM-1 (B) tumors in nude mice in Experiment #1 . The mice received a subcutaneous injection of 0.06 
(•), 0 .6 (o) , 6 (•), or 60 (6) µg of PEG-IFN-a2a, or medium alone (Control) (□), once a week for 2 
consecutive weeks. The arrows show the days of injection. The figures represent average ± SE. *P < 
0.0001 , versus the other groups. tP < 0.01 , versus the other groups. 
Table 2 .  The weight of subcutaneous tumors of HAK-1 B or KIM-1 cells in nude mice at kill ing 
Experiment #1 
Tumor weight (g) 
Treatment groupa HAK-1 B KIM-1 
Control o.303 ± 0 .05b , c 1 .050 ± 0.248 
PEG-IFN-a2a (0 .06 µg) 0 . 141 ± 0.03d 0 .725 ± 0 . 1 7' 
PEG-IFN-a2a (0.6 µg) 0.033 ± 0.01 0.439 ± 0 .04 
PEG-IFN-a2a (6 µg) 0.01 5 ± 0.01 0.434 ± 0.04 
PEG-IFN-a2a (60 µg) 0.0 0 .076 ± 0 .05 
a Cultured HAK-1 B or KIM-1 cells (1 .0  X 1 07) were subcutaneously transplanted into nude mice. Mice in 
each group were treated with once per week sucutaneous injections of phosphate buffered saline 
(Control) or  PEG-IFN-a2a. All mice were killed and the tumor weight was measured on the 1 5th day. b 
Mean ± SE .  c P < 0.02,  versus the PEG-IFN-a2a (0.06 µg) group; P < 0.001 , versus the PEG-IFN-a2a 
(0.6 µg) g roup; P < 0.001 , versus the PEG-IFN-a2a (6 µg) group. d. P < 0.02, versus PEG-IFN-a2a (60 
µg). e Not sign ificant, versus the PEG-IFN-a2a (0.06 µg) g roup; P < 0.03, versus the PEG-IFN-a2a (0.6 
µg) group;  P < 0.05, versus the PEG-IFN-a2a (6 µg) g roup; P < 0.01 , versus the PEG-IFN-a2a (60 µg) 
group. t P < 0.05, versus the PEG-IFN-a2a (60 µg) group.  
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IFN-a2a (0.0042 µg) 
IFN-a2a (0.042 µg) 
PEG-IFN-a2a (0.06 µg) 
Tumor weight (g) 
0. 726 ± 0.09b, c 
0.588 ± 0.07d 
0.531 ± 0.048 
0 .493 ± 0 .04f 
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PEG-IFN-a2a (0.6 µg) 0 .355 ± 0 .03 
a Cultured HAK-1 8 cells (1 .0 X 1 01) were subcutaneously transplanted into nude mice. Mice in each 
group were treated with once per week sucutaneous injections of phosphate buffered saline (Control) or 
IFN-a2a or PEG-IFN-a2a. All mice were killed and the tumor weight was measured on the 1 5th day. b 
Mean ± SE. c P < 0.005, versus the PEG-IFN-a2a (0.6 µg) group. d P < 0.02, versus the PEG-IFN-a2a 
(0.6 µg) group. e P < 0.03, versus the PEG-IFN-a2a (0.6 µg) group. t P < 0.02, versus the PEG-IFN-a2a 







Figure 4. Photomicrograph of subcutaneous human HCC tumor in nude mice that was developed after 
the injection of HAK-1 8 cells. (A) A control mouse that received culture medium alone. The tumor 
shows a compact arrangement of tumor cells and a sinusoid-l ike structure in the stroma. (8) A mouse 
that received a s.c. injection of 0 .06 µg of PEG-IFN-a2a. There are some apoptotic tumor-cells 
characterized by shrinkage and eosinophilic change in the cytoplasm, chromatin condensation and/or 
fragmentation of nuclei (arrows, HE staining, X200). (C) The same tumor as shown in (8). There are 
some TUNEL-positive cells showing brown nuclei (arrows, stained by the TUNEL technique, X200) .  
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Table 4. Numbers of apoptotic cells and BrdU-positive cells in human HCC tumors subcutaneously 
transplanted in nude mice 
Treatment groupa 
Control 
PEG-IFN-a2a (0.06 µg) 
Apoptosisb 
(Number of cells/0.25mm2) 
HE stain 
8.4 ± 0.8d , e 
1 2.2 ± 1 .0 
TUNEL method 
9.6 ± 1 . 1 e 
1 5 .4 ± 1 .8 
BrdU Labeling lndexc 
(Number of positive cells/0.25mm2) 
32.3 ± 1 .61 
27.0 ± 2.6 
PEG-IFN-a2a (0.6 µg) 1 2 .4 ± 0.9 1 6. 1  ± 1 .5 3 1 .3 ± 6.9 
a Cultured HAK-1 B cells ( 1 . 0  X 1 01) were subcutaneously transplanted into nude mice. Mice i n  each 
group were treated with once per week subcutaneous injections of phosphate buffered saline (Control) 
or PEG-IFN-a2a. Tumors of mice that received 6 or 60 µg of PEG-IFN-a2a could not be used because 
the tumors were too small to evaluate. All mice were killed on the 1 5th day. b The number of apoptotic 
cells was counted in at least three 0.25 mm2-areas in each section stained with hematoxylin and eosin, 
and the average n umber per area in  each group was obtained. The n umber of TUNEL-positive cells 
was also counted in the same manner. c The number of BrdU-positive cells was counted in at least three 
0.25 mm2-areas in each section, and the average number per area in each g roup was obtained as the 
labeling index. d Mean ± SE.  e P < 0.02, versus the other groups. 1 Not significant, versus the other 
groups. 
Figure 5. Photomicrograph showing double immunostained artery-like blood vessels in a subcutaneous 
human HCC tumor developed after the injection of HAK-1 B cells. (A) 
Photomicrograph of a subcutaneous HAK-1 B tumor in a nude mouse that received a s.c. injection of 
0.06 µg of PEG-IFN-a2a showing small artery-like blood vessels in the scar (arrows, HE staining, X200). 




Table 5. Numbers of artery-like blood vessels, and Enzyme-linked immunosorbent assay (ELISA) of 
angiogenesis factors in human HCC tumors subcutaneously transplanted in nude mice 
Treatment group0 
Artery-like blood vesselb 
(Number of vessels/mm2) 
I nside of around 
the tumor the tumor total number 
Levels in the tumor lysatec 
(pg/40 µg cel lular protein) 
bFGF I L-8 
Control 0.274 ± 0.09d, e 1 . 14  ± 0.251 1 .41 ± 0.33g 1 4.0 ± 1 .81 2.8 ± 1 .01 
PEG-IFN-a2a 
(0.06 µg) 0 .868 ± 0 . 1 6  1 .30 ± 0.29 2 . 1 7  ± 0.43 1 9.8 ± 2 . 1  4.9 ± 1 .3 
PEG-IFN-a2a 
(0.6 µg) 1 .87 ± 1 .45 2 .36 ± 0.88 4.23 ± 2 . 14  
a Cultured HAK-1 B cells (1 .0 X 1 01) were subcutaneously transplanted into nude mice. Mice in  each 
group were treated with once per week subcutaneous injections of phosphate buffered saline (Control) 
or PEG-IFN-a2a. Tumors of mice that received 6 or 60 µg of PEG-IFN-a2a could not be used because 
the tumors were too small to evaluate. All mice were kil led on the 1 5th day. b The number of blood 
vessels in and around the tumor nodule was counted on each section, and the average number per 
area in each group was obtained. c The expression levels of basic fibroblast growth factor (bFGF) and 
IL-8 of the resected tumors were measured by ELISA. d Mean ± SE. e P < 0.002, versus the PEG-IFN­
a2a (0.06 µg) group; P<0.05, versus the PEG-IFN-a2a (0.6 µg) group. 1. Not significant, versus the other 
groups. g P < 0.05, versus the PEG-IFN-a2a (0.6 µg) group. 
Discussion 
In the in vitro study , we showed that PEG- I FN-a2a inhibit the growth of 8 and 11 
out of 13 cell lines in a time- and dose-dependent manner , however , PEG- I FN-a2a 
was apparently less active on an IC50 basis, compared with either PEG- I FN-a2b or 
I FN-a2b or consensus I FN-a or BALL-1 lymphoblastoid I FN-a which was tested in 
the same experimental condition in our previous reports [10 , 18 , 21] .  For example , 
IC50 for HAK-1 B cells was approximately 253 ng/ml of PEG- I FN-a2a , 13 .1 ng/ml of 
PEG- I FN-a2b , 2 .4 ng/ml of I FN-a2b , 0 .  7 ng/ml of consensus I FN-a and 1 .1 ng/ml 
of BALL-1 lymphoblastoid I FN-a .  On the other hand , in the in vivo study , s .c .  
injection of PEG- I FN-a2a once a week showed better antitumor effect on a tumor 
volume or weight basis , compared with that of non-pegylated I FN-a2a. These 
results might support our hypothesis that continuous contact with I FNs induces 
strong in vivo antitumor effects , and are not surprising because it was reported that 
PEG- I FN-a2a showed less active in vitro antiviral activity and but had much more 
in vivo antitumor activity than non-pegylated I FN-a2a [23] .  Another interesting 
finding in the in vitro study is the discrepancy between the results of MTT assay 
and apoptosis detection assay . When HAK-1 B or K I M-1 was cultured with PEG­
I FN-a2a , IC50 for HAK-1 B was much lower than that for K I M-1 although HAK-1 B 
showed lower rate of apoptotic cells than K I M-1 .  These findings suggest that there 
might be some mechanisms other than apoptosis , which affect the sensitivity to 
antitumor effects of PEG- I FN-a2a. Factors related to the antitumor effect of I FNs 
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are still unclear. The expression of interferon receptor is one of the most studied 
factors. For instance, our previous report showed that IFN-a inhibited the 
proliferation of cultured HCC cells by inducing inhibition of cell-cycle progression 
with or without apoptosis, regardless of the expression level of type I IFN receptor 
beta chain [18]. On the other hand, Nagano et al reported that the expression of 
this type I IFN receptor on HCC tissue might be a useful predictor to find potential 
responder to INF-a/5-fluorouracil combination therapy [24]. lmmunomodulation by 
IFNs has also been well studied as a factor related to antitumor effect. In this study, 
we used athymic mice, which lack mature T-cell, and human IFNs. Since IFNs are 
species-specific [25], we surmise that this immunomodulative effect is limited in our 
study, but this should be confirmed in the future study using mouse IFN. 
Morphological observation of the subcutaneous tumors of nude mice revealed 
that s.c. injection of PEG-IFN-a2a induce the significant increase of apoptotic cells 
compared with Control group. This result in the in vivo study is consistent with that 
in the in vitro study showing characteristic changes of apoptosis after adding PEG­
IFN-a2a. Although the inhibition of angiogenesis as well as the induction of 
apoptosis is regarded as one of the biological effects of IFNs, the number of artery­
like blood vessels of the subcutaneous tumors in the treatment group was higher 
than that in the Control group. There are three possible explanations of this finding. 
Firstly, PEG-IFN-a2a was less effective for mouse endothelial cells compared with 
human cancer cells due to the species specificity of human IFNs. Secondly, these 
vessels are reflecting the increased angiogenesis in the granulation tissue 
surrounding tumor. Lastly but not least, it might be difficult to visualize the alteration 
in the number of vessels in order to examine the efficacy of drugs that possess 
antiangiogenic activity. Hlatky et al explained in their review article that the reason 
is that the tightness of the coupling between vessel drop-out and tumor-cell drop­
out after the treatment is different [26]. We had observed similar findings in our 
previous report in which human HCC tumors subcutaneously transplanted in nude 
mice showed much apoptosis in either PEG-IFN-a2b or IFN-a2b treatment group 
compared with the Control group, but no significant difference in the number of 
blood vessels [1 O]. Kojiro et al also showed that s.c. injection of BALL-1 
lymphoblastoid IFN-a increase the number of artery-like blood vessels and the 
protein expression of bFGF within HCC xenograft tumors in spite of the significant 
decrease of actual tumor weight [27]. In contrast, Dinney et al showed that IFN-a2a 
decreases the blood vessel density and the expression of bFGF in orthotopic 
xenograft model of bladder tumor [28]. The reason for these contrary findings 
remains unclear and further evaluation with caution is needed by using different 
doses and types of IFNs and different cell lines. 
The association between IFN therapy and occurrence or recurrence of HCC has 
been investigated in some reports. HAL T-C trial group showed in their randomized 
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control trial in a large cohort that long-term PEG-IFN-a2a therapy does not reduce 
the incidence of HCC among patients with chronic HCV infection who have 
previously failed to achieve a sustained virologic response to therapy [29]. Among 
only patients with cirrhosis, long-term PEG-IFN-a2a therapy reduced a risk of HCC 
after a long-time observation [30]. EPIC study group also showed long-term PEG­
I FN-a2b therapy does not prevent HCC [31]. On the other hand, Nishiguchi et al 
reported that long-term IFN-a therapy after curative resection of HGV-related HCC 
prolongs the survival rate, although preventive effect of intrahepatic recurrence was 
marginal [32]. Sakaguchi et al also showed that among patients who underwent 
radical radiofrequency therapy for HGV-related HCC, long-term IFN-a2b therapy 
reduced the recurrent rate of HCC [4]. These reports with conflicting results may be 
suggesting that IFN therapy is effective only after the initial curative treatment of 
HGV-related HCC. In addition, there are several reports that support that IFN 
therapy prevents the development of HCC among patients with chronic HBV 
infection or those underwent curative resection of HBV-related HCC [5, 7]. 
In conclusion, we demonstrated antitumor effect of PEG-IFN-a2a for human 
liver cancer cells in vitro and in vivo and our results suggest that longer contact to 
IFNs may induce stronger antitumor effect in body. PEG-IFN-a2a might be a 
possible treatment option for HCC as well as chronic viral hepatitis. Further studies 
are needed from both molecular and clinical view points in order to find out 
particular patient group those respond to this therapy. 
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Hepatocellular carcinoma (HCC) is  the sixth most common cancer globally, and the 
third most common cause of cancer-related death . Most HCCs occur in a cirrhotic 
liver which develops as a consequence of longstanding inflammation, and this fact 
is an important factor that contrib utes to the limitations of therapeutic management 
of HCC. HCC treatment strategy is based not only on tumor status, e .g .  size and the 
number of tumor, b ut also on the patients ' residual liver f unction . According to the 
Barcelona Clinic Liver Cancer staging system, which is the most widely a pplied 
system, HCC patients at the very early or early stage can be candidates for 
potentially c urative treatment options, such as liver transplantation, s urgical 
resection, and radiofrequency ablation . One of the most important negative 
prognostic factors of s urgical treatment of HCC is the presence of microvascular 
invasion (micro-VI) .  Micro-VI is a frequent phenomenon for which there is no 
reliable preoperative predictive factor. Patients with advanced stage HCC, who 
unfortunately represent the major group of HCC patients at the time of diagnosis, 
have the limited option of palliative treatment . Sorafenib, an oral m ultikinase 
inhibitor, is the first and so far the only single systemic agent which can improve 
overall survival of patients with advanced HCC by several months . 
This thesis addresses two issues that influence the prognosis of HCC, micro-VI 
(Part I) and Interferon ( IFN) therapy (Part I I) .  
Part I: The significance of Microvascular invasion 
Micro-VI is currently regarded as an independent prognostic factor, and can only be 
identified by postoperative histopathological assessment due to its microscopic 
nature . In chapter 2 we reviewed the current status of methods to predict micro-VI 
preoperatively and the prognostic value of micro-VI in patients who underwent liver 
transplantation for HCC. Many studies reported the significant correlation between 
micro-VI and size and number of tumors . The likelihood of micro-VI can be 
predicted on the basis of tumor size and n umber preoperatively, however an 
important limitation is the difficulty of  accurate radiological assessment of  tumor size 
and number in a cirrhotic liver. The association of the gross appearance of HCC 
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with micro-VI has been reported repeatedly mainly by Japanese studies. However, 
a limitation is that it is still not possible to evaluate the gross type by conventional 
imaging modalities. New imaging modalities and serum biomarkers were also 
reviewed as a potential tool to predict micro-VI before surgery. It was noted that 
fluorodeoxyglucose positron emission tomography and the serum concentration of 
des-y-carboxy prothrombin can be predictive although further validation studies are 
needed. We concluded that micro-VI is an independent risk factor for recurrence 
and survival after liver transplantation and that currently there is no reliable 
predictive marker for micro-VI before surgery. 
Despite the significance of micro-VI, its molecular background remains obscure. 
Vascular invasion requires several processes at sites where the primary tumor 
develops: tumor cell proliferation; epithelial-mesenchymal transition (EMT); 
extracellular matrix degradation, cell migration and tumor angiogenesis. To 
establish a potential profile of micro-VI positive HCC, in chapter 3 ,  we investigated 
micro-VI in HCCs from the perspective of a 3-step process; tumor characteristics, 
angiogenesis and EMT We studied the gene expression profile of factors 
associated with these processes. High grade tumor, decreased E-cadherin 
expression on tumor cells, and an increased placental growth factor expression in 
non-cancerous peritumoral tissue were associated with the presence of micro-VI. In 
addition, in the micro-VI positive group the expression of placental growth factor and 
vascular endothelial growth factor receptor-1 was increased in peritumoral tissue 
compared with the corresponding HCC. The altered angiogenic status in 
peritumoral tissue highlighted the significance of the microenviron ment in which 
micro-VI develops and the possible crosstalk between cancer cells and tumor 
stroma. 
To further investigate the changes in tumor stroma associated with micro-VI, in 
chapter 4 we focused on the changes in the peritumoral fibrous septa which were 
collected by laser microdissection. We studied the expression pattern of the same 
set of genes as in chapter 3. Our results showed that in the micro-VI positive group 
there was a decreased gene expression of epithelial cell adhesion molecule 
(EpCAM) and E-cadherin within peritumoral septa compared with the expression in 
cirrhotic septa collected distant from the tumor. Septal EpCAM and E-cadherin 
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expression could only be found in biliary ductules since these were the only 
epithelial cell component present in the septa. Subsequent comparative 
quantification of septal ductules revealed that micro -VI positive H CC was 
associated with a significantly lower numbers of peritumoral ductules compared to 
the number of ductules in the corresponding distant septa . This finding may 
represent a potential tool to predict micro-VI in biopsies before surgery provided 
robust validation studies can confirm the association that we found. 
Part II: Systemic therapy for HCC: the role of interferon therapy 
It is well known that IFNs possess antitumor effect against certain types of cancer 
as well as antiviral activity. Pegylated IFN alpha (PEG- IFN-a) which has longer 
serum half-life in body than the conventional one is used to treat patients with 
hepatitis C virus infection in combination with a nucleoside analog, ribavirin as a 
standard care . In addition, it was reported that IFNa can prolong patient's su rvival in 
inoperable HCC. Combination therapy of PEG-IFN-a with sorafenib may have a 
potential to improve the outcome of sorafenib monotherapy. In chapter 5, we 
investigated the antiproliferative effects of combination therapy of sorafenib and 
PEG- IFN-a2b on two human HCC cell-lines in vitro and in vivo. In the in vitro study, 
a synergistic or additive antiproliferative effect of combination therapy was seen. In 
the in vivo study, a significant reduction of tumor volume and weight was observed 
in the combination group, although the effect of the monotherapy group was not 
always significant. In chapter 6, we investigated the effects of PEG-IFN-a2a on the 
growth of human liver cancer cells. PEG-IFN-a2a inhibited the growth in vitro, and 
its 50% growth inhibitory concentrations were higher than non-pegylated IFN-a2a. 
On the other hand , PEG-IFN-a2a showed better antiproliferative effect in the in vivo 
study than non-pegylated one possibly due to their unique pharmacokinetics. These 
findings in chapter 5 and 6 suggest that PEG-IFNs might be potential agents for the 
treatment of HCC with or without sorafenib . The different sensitivities of various 
HCC cell-lines to IFN or sorafenib therapy also suggest that molecular profiling of 







Hepatocellulair carcinoom (HCC) staat wereldwijd op de zesde plaats van de meest 
voorkomende kanker soort en op de derde plaats van de meest voorkomende 
kanker gerelateerde doodsoorzaak. De meeste HCCs komen voor in cirrotische 
levers die het gevolg zijn van een langdurig ontstekingsproces en dit is een 
belangrijke factor die bijdraagt aan de beperkingen van de therapeutische 
mogelijkheden voor HCC. Het behandelbeleid van HCC is niet alleen gebaseerd op 
de tumorstatus, zeals grootte en aantallen tumor nodi, maar ook op de status van 
de leverfuncties van de patient. Volgens het meest toegepaste Barcelona Clinic 
Liver Cancer stageringsschema zouden HCC patienten die zich in het zeer vroege 
stadium bevinden of in het vroege stadium, kandidaten zijn voor een potentieel 
curatieve therapeutische optie zoals lever transplantatie (LT), chirurgische resectie 
en radio frequency ablation. Een van de belangrijkste negatieve prognostische 
factoren van de chirurgische therapie van HCC is microvasculaire invasie (micro-VI). 
Micro-VI is een frequent fenomeen waarvoor geen betrouwbare preoperatieve 
voorspellende methode bestaat. Patienten met een gevorderd stadium van HCC, 
die helaas het grootste deel van de HCC patienten vertegenwoordigen ten tijde van 
de diagnose, hebben een beperkte optie van palliatieve behandeling. Sorafenib, 
een orale multikinase remmer is het eerste en tot dusver enige systemische middel 
die tot een verbetering van de overall overleving van enkele maanden kan leiden bij 
HCC patienten in een gevorderd stadium. 
In dit proefschrift behandelen we 2 onderwerpen die invloed hebben op de 
prognose van HCC, namelijk micro-VI (deel I) en Interferon (IFN) therapie (deel II). 
Deel I: De rol van Microvasculaire lnvasie 
Micro-VI wordt tegenwoordig beschouwd als een onafhankelijk prognostische factor 
maar kan vanwege de microscopische aard ervan pas postoperatief worden 
vastgesteld bij histologisch onderzoek van de gereseceerde tumor. Hoofdstuk 2 is 
een overzicht waarin we de huidige stand van zaken betreffende de preoperatieve 
opsporingsmethoden van micro-VI hebben geevalueerd evenals de prognostische 
waarde van micro-VI bij patienten met HCC die een LT hebben ondergaan. In veel 
studies werd een significante correlatie gezien tussen micro-VI en de grootte van de 
tumor en het aantal tumornodi. De mogelijke aanwezigheid van micro-VI kan 
preoperatief worden voorspeld op basis van de grootte en het aantal tumoren 
maar een nauwkeurige radiologische evaluatie van deze twee eigenschappen is in 
een cirrotische lever bijzonder moeilijk. In veel Japanse studies werd het verband 
gelegd tussen het macroscopisch aspect van de tumor met micro-VI maar de 
beperkende factor is het feit dat het nog steeds niet mogelijk is om het 
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macroscopisch aspect van de tumor preoperatief vast te stellen met de huidige 
imaging technieken. Bij de evaluatie van nieuwe imaging technieken en serum 
biomarkers kwamen fluorodeoxyglucose positron emission tomography en serum 
gehalte van des-y-carboxy prothromb in naar voren als potentiele mogelijkheden 
voor preoperatieve vaststelling van micro-VI. Verdere validatie studies zijn echter 
noodzakelijk. We kwamen tot de conclusie dat micro-VI een onafhankelijke 
risicofactor is voor HCC recurrens na LT die de survival negatief be·invloedt en 
waarvoor tegenwoordig nag geen betrouwbare middel bestaat voor de 
preoperatieve opsporing ervan. 
Ondanks het feit dat micro-VI een belangrijk fenomeen is, is er weinig bekend over 
de moleculaire achtergrond ervan. Vasculaire invasie omvat meerdere processen 
op de plaats waar de primaire tumor zich ontwikkelt: tumorcel proliferatie, 
epitheliale-mesenchymale transitie (EMT}, extracellulaire matrix degeneratie, 
celmigratie en tumorangiogenese. In hoofdstuk 3 hebben we getracht een 
moleculair profiel op te stellen van micro-VI positieve HCC. Hiervoor onderzochten 
we micro-VI in HCC vanuit het perspectief van een 3-staps proces dat de tumor 
eigenschappen, EMT en angiogenese omvat. We onderzochten het 
genexpressieprofiel dat geassocieerd is met deze 3 processen. Het voorkomen 
van micro-VI bleek te zijn geassocieerd met een hoge tumorgraad, verlaagde 
E-cadherin expressie in tumorcellen en een toegenomen expressie van placental 
growth factor in het leverweefsel naast de tumor. Daarnaast werd in de micro-VI 
positieve HCC groep een hogere expressie gezien van placental growth factor en 
vascular endothelial growth factor receptor- 1 in het peritumorale leverweefsel ten 
opzichte van de daarnaast gelegen HCC. Van placental growth factor is bekend dat 
het pathologische angiogenese stimuleert. De veranderde angiogene status in het 
peritumorale leverweefsel benadrukt de belangrijke rol van de micro-omgeving 
waarin micro-VI plaats vindt en de crosstalk tussen kankercellen en tumorstroma. 
Verder onderzoek naar veranderingen in het tumorstroma werd verricht in 
hoofdstuk 4. In dit onderzoek werd peritumoraal fibreus stroma ge·isoleerd 
middels lasermicrodissectie en hierin werd het expressiepatroon van dezelfde 
groep genen als in hoofdstuk 3 onderzocht. In het peritumorale stroma van de 
micro-VI positieve HCC groep werd een verlaagde expressie gezien van epithelial 
cell adesion molecule (EpCAM) en E-cadherin in vergelijking met de expressie in 
het fibreuze stroma afkomstig van cirrhotische septa die verder van de tumor 
gelegen waren. EpCAM en E-cadherin kunnen in fibreuze septa uitsluitend tot 
expressie komen in biliaire ductuli omdat deze de enige epitheliale cellen herbergen 
die in dit compartiment aanwezig kunnen zijn. De kwantitatieve vervolgstudie 
toonde aan dat micro-VI positieve HCC geassocieerd was met een significant lager 
aantal ductuli in het peritumorale stroma ten opzichte van het verder gelegen 
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c irrhotische stroma. Deze bev inding zou een mogelijkheid kunnen b ieden om 
micro-VI in b iopten preoperatief te kunnen voorspellen als de resultaten goed zijn 
gevalideerd. 
Deel II: systemische therapie van HCC: de rol van interferon therapie 
Het is bekend dat interferon ( IFN) zowel een antitumor effect heeft ten opzichte van 
een aantal kankersoorten als een antiv irale activ ite it . Gepegyleerd IFN alpha 
(Peg-lFN-a) dat een langere halfwaarde t ijd heeft in het l ichaam dan de 
conventionele types wordt in comb inatie met een nucleoside analoog , r ibav ir in , 
gebru ikt als standaard behandeling van hepatitis C. Daarnaast werd 
I FN-a genoemd als een mid de I dat de overlev ing kan verlengen van pat ienten met 
een inoperabele HCC. Op grond h iervan kwamen we tot de hypothese dat een 
combinatie therapie van Sorafenib met Peg-lFN-a het effect van Sorafenib 
monotherapie zou kunnen verbeteren . In hoofdstuk 5 werd het antiproliferatie 
effect van de combinatie van Sorafenib en Peg-lFN-a2b onderzocht op 2 humane 
HCC cellijnen zowel in vitro als in vivo. In de in vitro studie werd een synergist isch of 
additief effect van de comb inatie therap ie gezien. In het in vivo deel werd een 
s ignif icante reductie gezien van het volume en gewicht van de tumor in de 
comb inat ie-therap ie groep , maar er was geen synerg istisch effect . In hoofdstuk 6 
werd het effect onderzocht van Peg-lFN-a2a op de groei van humane HCC cell ijnen. 
Peg-lFN-a2a remde de groei in vitro, en de 50% groeiremmende concentraties 
waren hoger dan ongepegyleerd IFN-a2a . Maar ongepegyleerd Peg-lFN-a2a 
toonde wel een beter antiproliferatie effect in het in vivo model dan IFN-a2a ,  
vermoedel ijk door de verschillen in hun farmacokinetiek. De bev indingen van de 
hoofdstukken 5 en 6 suggereren dat PEG- IFN potent iele middelen zouden kunnen 
zijn voor de behandeling van HCC met of zonder Sorafenib . De verschillende 
gevoel igheden van de verschillende HCC cellijnen ten opzichte van IFN en 
Sorafenib therapie suggereren ook dat moleculaire profiling van de tumor 
noodzakelijk zal zijn voor een betere afstemming tussen de tumor en de 
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